HIV-TREATMENT METHOD WITH LOW-TOXICITY AMPHOTERICIN B

Abstract: A method of inhibiting HIV infection in peripheral blood macrophages, as evidenced by an inhibition of HIV p24 antigen expression in the infected cells. The method includes exposing the infected macrophages to a composition containing particles of amphotericin B:cholesteryl sulfate, molar ratio 1:0.5 to 1:4, at a concentration of at least about 0.01 mu M amphotericin B.

Description: HIV-TREATMENT METHOD WITH LOW-TOXICITY AMPHOTERICIN B 1. Field of the Invention The present invention relates to a method of inhibiting HIV infection in HIV-infected peripheral blood cells. 2. References 1. Holz, R.W. , in F.F. Hahn, Fd. , Antibiotics Vol. 2 , Springer-Verlag, N.Y. (1979) . 2. Trembley, C. , et al., An imicrob. Agents Chemoth. 26(2) :17D (1984). 3. Mehta, R.T., et al., Infection and Immuni¬ ty, 47(2) :429 (1985). 4. Lopez-Berestein, G. , et al., Cancer Drug Delivery, 1(1) :37 (1983). 5. New, R.R.c, et al., J. Antimicrob. Chemo¬ th. 8:371 (1981). 6. Graybill, J.R. , et al., J. Infect. Dis., 145:5 (1982). 7. Lopez-Berestein, G. , J. Infect Dis., 150(2) :278 (1984). 8. Trembley, c, et al., Invest. Opthalmol. 26:711 (1985). 9. Lopez-Berestein, G. , et al., J. Infect. Dis. 151(4) :7D4 (1985). 10. Juliano, R., et al., Biology of the cell, 4(39) (1983). 11. Mehta, R. , et al, Biochim. Biophys. Acta. 770:230 (1984) . 12. Hopfer, R.L., et al., Antimicrob. Agents Chemoth. 25(3) :387 (1984). 13. Brockerhoff, H. et al., Biochim. Biophys. Acta, 691:227 (1982). 14. Crowe, L.M. , et al., Biochim. Biophys. Acta 769:141 (1984) . 15. Remington's Pharmaceutical Sciences, Gennaro, A.R. , ed. , Mack Publishing company (1985) . 16. Hoffman, A.E., et al., Virology 147:326 (1985) . 17. Wang, C. Y. , et al., U.S. Patent No. 4,879,212, issued 7 NOV. 1989. 18. Wang, C. Y. , et al., U.S. Patent No. 4,735,896, issued 5 April 1988. 19. Crowe, S. M. , et al., AIDS Res. Hum. Retroviruses 6(8):1031 (1990). 20. Locksley, R. M. , et al., J. Clin. Invest. 82(6):2097 (1988). 21. Koenig, S., et al.. Science 233:1089 (1986) . 22. Ausubel, F. M. , et al., Current Protocols in Molecular Biolocry. John Wiley and Sons, Inc., Media PA. 23. Crowe, S. M. , et al., J. Med. Virol. 29(3) :176 (1989). 24. Lifson, J. D., et al. , U.S. Patent No. 4,869,903, issued 26 Sept. 1989. 25. Coffin, J., et al.. Science 232:697 (1986) . 26. Fahey, J.L., Am. J. Med. 76:95 (1984). 27. Steicher, H.Z., et al., JAMA 256:2390 (1986). 28. Armstrong, W.H., presented at "The Inter¬ national Conference on AIDS," 23-25 June, 1986. 29. Crowe, S. M. , et al., AIDS Res. Hum. Retroviruses 3(2):135 (1987). 30. Meltzer, M. , et al., Annu. Rev. Immunol. 8:169-94 (1990). 31. Bender, B., et al.. Rev. Inf. Diseases 10- (6):1142 (1988). 32. Perno, C-F. , et al., J. Exp. Med 169:933- 951 (1989) . 33. Yarchoan, R. , et al.. New Eng. J. Med. 321:726-738 (1989). 34. Moore, N. , et al., J. Virol 27:320-329 (1978) . 35. Sarin, P., et al.. Lancet 313:1289 (1985). 36. Abrell, J. and Gallo, R. , J. Virol. 12:421-439 (1973). 37. Sanders, S., et al., Antimicrob. Agents Chemother. 35:1029-1034 (1991). 3. Backcrround of the Invention Amphotericin B (AMB) is an effective antifungal agent, which at present is the drug of choice for the treatment of a variety of life-threatening systemic fungal infections (1) . The drug is present- ly available for human use as a lyophilized powder consisting of a mixture of AMB and deoxycholate known under the trade name "Fungizone." The AMB is known to enter fungal cells and bind strongly to ergosterol, a major sterol component of fungal cell membranes. Ergosterol-bound AMB forms pores in the fungal cell membranes which leads to lysis and cell death. The AMB also has a strong binding affinity for cholesterol, a sterol present in most mammalian cell membranes, and is therefore capable disrupting and damaging host cells. When AMB is administered in free form, i.e., as a reconstituted AMB/deoxycholate complex, severe side effects are observed. Acute side effects include fever, chills and pain at the site of injection. Dose limiting adverse effects are severe damage to the kidney and anemia caused by hemolysis of red blood cells. Several studies have shown that AMB toxicity can be reduced by administering the drug in a lipo- some- bound form (Ref. 2-12) . Typically, the ~ O X of AMB increases from about 2-3 mg/kg body weight for the free drug up to about 8-15 mg/kg when the drug is administered in liposomal form. One limitation of liposomal formulations, however, is the apparent size instability of Amphotericin B/liposomal parti¬ cles observed when stored in an aqueous medium. Typically, AMB-containing liposomes which have an initial size distribution between about 100-300 nm will spontaneously form aggregates or large lipo- somal structures of up to several microns on long— term storage in an aqueous medium. Liposomes with sizes greater than about 1-2 microns are generally more toxic than smaller liposomes when administered parenterally, i.e., into the bloodstream. The toxicity of large liposomes in the blood¬ stream is related in part to liposome blockage of the alveolar capillaries or capillaries in a periph¬ eral circulation. There are also indications that relatively large liposomes are more toxic to the liver, presumably due to liposome accumulation in reticuloendothelial cells. Co-owned U.S. Patent 4,766,096 for "Stabilized Liposome/Amphotericin composition and Method," discloses a novel method of preparing and storing AMB liposomes which largely overcomes the size-growth problem mentioned above. An AMB composition formed by complexing AMB with a polyethyleneglycol (PEG) derivative of cho- lesterol has also been proposed (PCT application US84/00855) . This formulation increased the LD^, of AMB to 10.0 mg/kg in mice, from 3.8 mg/kg for Fungizone, and was also less cytotoxic in cell culture. It is not known how and whether AMB complexing to PEG-cholesterol affects therapeutic efficacy against fungal infection in vivo, nor whether the complex can be stored in a size-stable form. More recently, an AMB/cholesteryl sulfate composition sulfate containing a drug:lipid mole ratio of between about 1:1 and 1:4 has been dis¬ closed (U.S. Patent No. 4,822,777). The toxicity of the composition, as measured by LD^ in model ani¬ mals, is substantially lower than that of other reported AMB/lipid compositions, as seen from toxicity studies described below. The composition is therapeutically effective against a number of fungal infections, also as described below. Fur¬ ther, the composition is relatively size stable in solution, and the particle sizes in the composition are favorable for parenteral drug administration. It has now been found, in accordance with the present invention, that the low-toxicity AMB/choles- teryl sulfate composition previously reported is effective to inhibit replication of human immunode¬ ficiency virus (HIV) in infected peripheral blood cells, such as monocyte-derived macrophages. HIV is the etiological agent associated with the syndrome of diseases known as acquired immune deficiency (AIDS) and related disorders (25) . The host cell range for HIV includes, CD4 T-lymphocyte cells, cells of the mononuclear phagocytic lineage (includ¬ ing monocytes-macrophage) , tissue macrophage (27) , Langerhans cells, and dendritic reticulum cells (28) of the lymph nodes. Monocyte-macrophage cells are likely a major reservoir of HIV in vivo. Further, the monocyte-macrophage cells, either alone or through their interactions with T-cellε, may con- tribute to the development and pathogenesis of HIV related diseases (29) . 4. fiiϊ_nwarγ of the Invention In one aspect, the invention includes a method of inhibiting HIV infection in peripheral blood macrophages, as evidenced by an inhibition of HIV p24 antigen expression in the infected cells. The method includes exposing the infected macrophages to a composition containing particles of AMB:choleste- ryl sulfate, molar ratio 1:0.5 to 1:4, at a concen¬ tration of at least about 0.01 μM AMB. In a pre- ferred method, the composition contains AMB:choles- teryl sulfate at a molar ratio of 1:1 to 1:2, and particle sizes between about 40-150 nm. The method may be used for treating a human subject infected with HIV, where the amount of composition administered preferably contains about 0.25-3.0 mg AMB/kg human subject. The treatment method may be carried out by repeated dosing with the composition, until there is produced a measur¬ able improvement in at least one of the indications of HIV infection: (a) a decrease in HIV antigen levels associated with HIV-infected cells; (b) a decrease in HIV antigen levels in the bloodstream (antigenemia) ; (c) a decrease in the titer of HIV particles in the bloodstream (viremia) ; (c) a decrease in the level of reverse-tran- scriptase activity associated with HIV-infected cells. (d) a decrease in the rate of HIV-induced destruction of CD4 positive T helper lymphocytes; or (e) an increase in the absolute number of CD4 positive T helper lymphocytes in the peripheral circulation. In another aspect, the invention includes a novel method for producing the AMB/cholesteryl sulfate composition, by solvent-injection. In this method, AMB and cholesteryl sulfate are dissolved in DMSO, and injected into an aqueous phase buffer. By selectively controlling injection temperature, aqueous-phase mixing, injection and post-injection incubation times, particles of desired selected sizes, e.g., approximately 100 nm, can be produced. These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings. Brief Description of Drawings Figure 1 is a flow chart showing steps in the process for the commercial-scale production of a 1:1 AMB/cholesteryl sulfate composition; Figure 2 shows the effect of temperature on AMB/cholesterol-sulfate particle sizes in a solvent injection method; Figure 3 shows the effect of mixing Reynold's number on AMB/cholesterol-sulfate particle sizes in the solvent injection method; Figure 4 shows the effect of injection time and post-injection incubation time on AMB/cholesterol- sulfate particle sizes in the solvent injection method; Figure 5 shows electron microscopic images (x 60,000) of negatively stained colloidal dispersions of AMB/cholesteryl sulfate, where the inset shows particle size distribution of the sample; Figure 6 are graphs showing the inhibition of p24 production in HIV infected macrophage cells treated with AZT; Figure 7 is a graph showing the inhibition of HIV p24 antigen expression in macrophage infected macrophages following treatment with AMB/cholesteryl sulfate colloidal dispersion; and Figure 8 is a graph showing the effect of AMB/cholesteryl sulfate dispersion treatment on the viability of the treated macrophages Detailed Description of the Invention I. Preparing AMB/Cholesteryl sulfate Particles This section describes two preferred methods for preparing an AMB/cholesteryl sulfate particle composition for use in the present invention. A. Thin-Film Hvdration Method In this preparation method, AMB and cholesteryl sulfate are combined in dry form or in solution at a selected mole ratio of amphotericin B:cholesteryl sulfate of about 1:0.5 to 1:4. A solution of AMB/cholesterol derivative in DMSO (dimethylsulfox¬ ide) , ethanol, ethanol or a combination of these solvents is dried to a thin film by removing the solvent. The film can be formed from a solvent solution containing a micronized suspension of bulking agent particles (such as lactose) , yielding dried parti¬ cles of the agent coated with the lipid mixture. Solvent removal is by vacuum evaporation or under a stream of inert gas, e.g., nitrogen. The dried lipid film may be stored under an inert gas, prefer¬ ably at 4°C or less. An aqueous particle suspension is formed by addition of an aqueous medium to the dried lipid mixture. The medium used in Example 1, containing 10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4 is suitable. The amount of medium added is sufficient to produce a final AMB concentration of preferably between about 25-100 /.mole/ml. Initially, the lipid material is suspended in the aqueous medium crudely by mechanical agitation until the lipid clumps are released into the aqueous medium to form a slurry-like mixture. This material is then dispersed to a fine particle sizes by sonication, homogenization, French press or other suitable high-energy processing methods. The homogenization process is carried out until a desired particle size, preferably between 40-120 nm is achieved. The suspension may be warmed during dispersion, and should be maintained under an inert atmosphere. In the method described in Example 1, the suspension is sonicated at 4°C to virtual optical clarity. Final particle sizes were between 100-200 nm. Formulations containing less than about 1 mole cholesteryl sulfate per mole AMB do not sonicate to optical clarity, indicating that optimal dispersion requires at least a stoichiometric amount of cholesterol derivative. However, compositions containing a mole ratio of AMB:cholesteryl sulfate of as low as 1:0.5 have been found to have reduced toxicity and desired size characteristics. The particle suspension may be treated, such as with any molecular sieve chromatography, dialysis or diafiltration, to remove traces of free AMB. The dialysis conditions noted in Example 1 are suitable. The dialyzed material may be lyophilized, for storage, and reconstituted in a suitable injection medium prior to use as a parenteral injectable, as described below. The final concentration of AMB in the dispersed particle suspension can be determined by diluting an aliquot of the suspension in methanol and measuring AMB spectrophotometrically at 406 nm. Typical AMB concentrations at various stages of the preparation of the dispersion are given in Table 1 in Example 1 below. The dried particle formulation can be prepared either by lyophilization or spray drying. In the former method, the small particle suspension is frozen and lyophilized at a shelf temperature of preferably 2°C or less, as described in Example 1. The effect of lyophilizing on particle size is seen in Table 2 in Example 2, for each of four formula¬ tions having AMB:cholesteryl sulfate formulations having molar ratios between 1:1 and 1:4. In each case, mean particle sizes increased from about 100-200 nm before lyophilization, to between 200-300 after lyophilization and rehydration with water. The stability of the particles, pre and post lyophi¬ lization is considered below. For spray drying, the particle suspension is dried in a conventional apparatus in which the particles to be dried are sprayed in aerosolized suspension form into a stream of heated air or inert gas, and the aerosolized droplets are dried in the gas stream as they are carried toward a plate collector where the dried liposomes are collected. An exemplary spray dry apparatus is a Buchi 190 Mini Spray Dryer. The drying temperature is at least about 37oC, and preferably between about 40-50°C. The tempera¬ ture of the collection chamber is generally lower than that of the heated air, and typically about 37°C. The dried particles are collected and stored in dehydrated form, under an inert atmosphere. B. Solvent-Injection Method A preferred method for the large-scale produc¬ tion of the AMB/cholesteryl sulfate composition for use in the invention is by solvent injection. The preparation will be described with reference to Figure 1, which shows a flow diagram of the steps in the method. Initially, AMB and cholesteryl sulfate, at a selected molar ratio between 1:0.5 and 1:4 (e.g., 1:1), are dissolved in suitable solvent, such as DMSO (dimethyl sulfoxide) , or DMSO containing ethanol and/or methanol. The solution may be prepared by heating, e.g., at 50-55° for 0.5-1.5 hours. After solubilization, the mixture is prefer¬ ably filtered through a 1.2 μ filter to remove particulate material. The solution of AMB and cholesteryl sulfate is then injected under selected solvent-injection conditions into a suitable aqueous medium. Among the important parameters which have been found to affect final size distribution of the AMB/choleste¬ ryl sulfate particles, in accordance with the invention, are: (a) solvent-injection temperature; (b) aqueous-phase mixing during solvent injection; (c) injection time; and (d) post-injection incuba- tion time. Studies conducted in support of the method indicate that particle size in the final dispersion is relatively unaffected by changes in AMB concentrations, in the range 25-30 mg/ml, and changes in final DMSO concentrations, at DMSO concentrations between about 5-10% by weight. It was also shown that particle size is relatively unaffected by the degree of turbulent flow as it injected from a solvent tube into the aqueous medium, and size of injection tube nozzle. The effect of injection temperature (the temperature of both the injected and aqueous phases) on particle is shown in Figure 2, as a function of injection time. As seen, final particle size was directly related to injection temperature, with the smallest sizes (open circles) being achieved at the highest injection temperatures. Thus, in accordance with one aspect of the preparation method of the invention, it has been discovered that AMB/choleste- ryl sulfate particles in the molar range specified above can be prepared in selected size ranges, such as about 40-150 nm, by adjusting the temperature of the injected and aqueous phases during solvent injection. The mixing within the solvent-receiving vessel can be characterized by a Reynold's number, which a dimensionless number indicating degree of turbulent flow. As seen in Figure 3, higher Reynold's numbers lead to smaller particle sizes. The total injection time, i.e., the time required for complete solvent injection into the aqueous phase, has a significant effect on particle size. Figure 4 shows plots of AMB/cholesteryl sulfate particle size as a function of injection time. The particle size growth observed can be divided into two phases. The first occurs during actual solvent injection, and shows a linear in¬ crease in particle size with time. As seen in the figure, particle size generally increases with increasing injection time, over the 9-495 second times examined. The second phase of particle growth after injection is completed and shows a quadratic behav¬ ior in particle size increase with time. The rate of particle size growth as a function of time is slower during this second phase than during the first. The data for Figure 4 was taken at an injection temperature of between 50-55°C. To arrest the size growth of particles during the second phase, the dispersion is cooled to below 30°C. Thus, to achieve a selected particle size, both injection time and post-injection incubation time can be selectively varied. After solvent injection and incubation is com- plete, the dispersion is concentrated about 4 fold, then treated by diafiltration to remove solvent, e.g., DMSO, as indicated in the flow diagram in Figure 1. This process results in the spontaneous formation of disc-shaped AMB/cholesteryl sulfate particles having the selected sizes determined by the above-discussed solvent-injection conditions. Figure 5 shows electron microscopic images (x 60,000) of negatively stained colloidal dispersions of AMB/cholesteryl sulfate formed in accordance with the present solvent-injection method. As seen, the particles are disc-shaped, and in this particular composition, have particle sizes between about 80- 120nm. The dispersion formed above is further concen- trated by ultrafiltration and the solvent removed by dialysis (diafiltration) . The volume is adjusted by the addition of buffer to a AMB concentration of 5 mg/ml and the suspension filtered through a 0.45 micron prefilter. The suspension is further fil- tered through a 0.22 micron filter and subsequently sterilized by passage through a second sterile 0.22 micron filter. For use in commercial distribution, the sterile suspension is filled into vials (21.5 ml per vial) and lyophilized under aseptic conditions. The lyophilized preparation is stable in excess of two years when vials are stored at room temperature or below. Prior to administration, the suspension is reconstituted by the addition of sterile water. II. Physical Characteristics of AMB/Cholesteryl sulfate Composition This section examines the size stability of AMB:cholesteryl sulfate particle suspensions formed by the two methods described above. A. Particle-Size Stability In the first study, reported in Example 2, AMB:cholesteryl sulfate particles having molar ratios of AMB:cholesteryl sulfate of 1:1, 1:2, 1:3, and 1:4 were prepared by thin-film hydration (Exam¬ ple 1) and immediately after dialysis were stored for periods of up to 8 days at 4°C. The results are shown in Table 3. The 1:1 formulation was substan- tially stable over the 8-day test period, whereas the other formulations showed progressively greater size increases with increasing mole ratios of cho¬ lesteryl sulfate. The size stability of the four formulations after lyophilization and rehydration was determined according to procedures described in Example 1. Size stability data for the eight day test is shown in Table 2 in Example 2. Interestingly, there was little difference in size stability among the four formulations, and for each formulation, mean parti¬ cle size increased at most about 2 fold over the eight day test period. The combined results from Tables 2 and 3 demonstrate that (a) lyophilized AMB/cholesterol particles can be reconstituted with little increase in mean size and size distribution and (b) the particles in the reconstituted suspen¬ sion are relatively stable on storage in solution over a several-day period. The effect of physiological-strength saline and plasma on the size characteristics of the particles was also examined, as reported in Example 2. In a first study, the four post-dialysis AMB/cholesterol derivative formulations from above were diluted in 0.9% saline, and the particle sizes examined immedi- ately thereafter. As shown in the top row in Table 4, all of the particles showed a large size in¬ crease, although the 1:1 formulation was less aggregated. A similar study on post-lyophilization particles was also carried out, with the results shown in the top row of Table 5 in Example 2. A comparison of the data in Tables 4 and 5 shows that the 1:1 formulation is substantially more size stable in saline after lyophilization than post-dia¬ lysis. The other three formulations, having greater cholesteryl sulfate mole ratios, showed large size increases in saline both pre and post lyophiliza¬ tion. A second study was designed to examine AMB/cho¬ lesteryl sulfate particle size in blood plasma, and the effect of subsequent dilution of the plasma medium with suspending buffer. Initially, each of the four samples (both pre and post lyophilization) were diluted 1:1 with human plasma, then diluted after a few minutes with suspending buffer contain- ing 10% lactose. Size measurements were made immediately after dilution, and again 20 minutes later. The results are shown in the bottom two rows of Tables 4 and 5 in Example 2. Summarizing the data, plasma caused a size increase in all of the formulations. Smallest size increases were seen in the 1:1 formulation, where particle sizes were less than 1 micron (i.e., 1000 nm) . The size increase produced on contact with plasma was at least par¬ tially reversible for all formulations except the 1:4 formulation, as evidenced by the significant reduction in particle size after 20 minutes incuba¬ tion in dilute form in suspension medium. There was little difference in the size behavior of particles in pre- and post-lyophilization formulations. The data above demonstrate that the AMB:choles¬ teryl sulfate formulation can be stored in dried form long term, without significant increase in size, on rehydration, or significant change in size stability in plasma. One significant advantage of the dried particles which was observed was substan¬ tially greater size stability on storage in buffer. Within the range of AMB: cholesteryl sulfate mole ratios which was examined, the 1:1 formulation, gave greatest size stability and smallest mean particle sizes under the various conditions examined. B. Stability of Particle Composition formed by Solvent Injection The long-term stability of the AMB;cholesteryl sulfate formulation formed, as above, by solvent injection was examined for both prelyophilized and lyophilized products. Based on the results of several ongoing stability studies, the prelyophili- zation liquid is stable at 8°C for at least 12 months and at 30°C for 4 months. The lyophilized form of AMB/cholesteryl sulfate dispersion is stable at 8°C and 30 β C for at least 12 months and 50°C for at least 6 months. Reconstituted AMB/cholesteryl sulfate dispersion is stable at 8°C or at ambient temperature, exposed to room light, for at least 7 days, and the reconstituted product is compatible with the stopper. Detailed stability data are summarized in Example 6. C. Nature of AMB:Cholesteryl sulfate Particles It has been previously reported that choleste¬ ryl sulfate is capable of forming lipid vesicles or liposomes on extended (several hour) sonication (13) . It was therefore of interest to determine whether the AMB cholesterol derivatives particles of the present invention are liposomal in form. For these studies, originally the 1:4 AMB/cholesteryl sulfate formulation was selected, since a relatively high ratio of cholesteryl sulfate is more likely to form liposomal structures. Subsequently, other derivatives were investigated in ratios from 1:1 to 1:4 AMB/cholesterol derivative. One characteristic of liposomes is a continuous lipid bilayer capable of encapsulating water-soluble solute molecules. Many water-soluble molecules, such as sugars and other marker solutes, are readily encapsulated in liposomes by preparing (dispersing) the liposomal lipids in an aqueous medium containing the marker solute. Smaller marker molecules, such as sugars, also tends to pass through lipid bilayer membranes slowly, as evidenced by equilibration of the solute between encapsulated and bulk phase aqueous compartments over a several-hour to several- day solute-exchange period. To test the ability of AMB/cholesterol deriva¬ tive (1:4) particles to encapsulate sucrose, the particles were prepared by dispersion in a medium containing W C sucrose. After sonication to optical clarity, the particles were separated from the suspending medium by molecular sieve chromatography. using a column sieving material which excludes particles in the size range of the AMB/cholesterol derivative particles. Details of the test are given in Example 3. Briefly, 95% of the AMB was associat- ed with the particles eluted in the void volume, but no detectable peak of radioactivity was associated with the particles. Based on this study, it appears that the particles do not form encapsulating liposomal structure, or alternatively, that the particles form very leaky structures. The latter explanation is unlikely, since (a) cholesterol tends to decrease permeability in liposomes to small water-soluble permeants, and (b) the pure cholesterol derivative liposomes which have been described in Ref. 13 have very low permeability. Studies on cholesterol hemisuccinate liposomes also show stable encapsula¬ tion of a variety of small water-soluble molecules (PCT patent application WO 85/05030) . Another characteristic feature of liposomes is the ability of isotonic liposomes to swell on injection into a hypotonic medium. Here the lipo¬ somes are acting as small osmometers in response to solute gradients across the bilayer membranes. Isotonic liposome swelling has been observed in li¬ posome prepared from a variety of cholesterol derivatives, including cholesterol-PEG, cholesteryl sulfate (13), cholesterol phosphate and cholesterol hemisuccinate liposomes (PCT patent application WO 85/05030) . Cholesterol-derivative liposomes show the expected increased absorbance when injected into increasingly dilute media, although these liposomes behave less like ideal osmometers than do liposomes formed from conventional phospholipid components. Each of the above four AMB/cholesteryl sulfate particle compositions from above (1:1, 1:2, 1:3, and 1:4 mole ratios) was prepared in 10% lactose. Both pre- and post- dialysis particles were tested for osmotic swelling in distilled water, comparing particle size immediately after dilution with particle size 20 minutes after dilution. The results are shown in Table 6 in Example 3. No swelling was observed in any of the particle formu- lations. The test supports the finding from the encapsulation studies above that the AMB/cholesterol derivative particles of the invention do not form closed vesicle structures. III. Reduced Toxicity of AMB:Cholesteryl sulfate Particles A. Preclinical Studies As previously reported (U.S. Patent No. 4,822,777), AMB:cholesteryl sulfate particles have a significantly reduced toxicity, when compared with a commercial AMB composition (Fungizone™) and AMB composition formulated in liposomes or other AMB: lipid formulations. Example 4 describes a number of toxicity studies carried out on AMB;cholesteryl sulfate compositions formed by thin-film hydration. In a first study, reported in Table 7 of Example 4, the LD-. of Fungizone™ was compared with that of a 1:4 AMB/cholesteryl sulfate composition. Based on the data shown in Table 7, the LD^ of the free AMB (Fungizone™) composition is between 1-4 mg/kg animal weight. This value is increased to between 15-25 mg/kg in the AMB cholesteryl sulfate composition. The data in Table 8 of Example 4 indicate that the 1:1 AMB:cholesteryl sulfate composition has an LD j - value well about 20 mg/ml, and greater than formula¬ tions having ratios between 1:2 and 1:4. The toxicity ( D X ) of 1:1 AMB:cholesteryl sulfate particles was compared with that of AMB compositions containing three other cholesterol esters or ethers: cholesterol phosphate, cholesteryl hemisuccinate, and cholesteryl-polyethyleneglycol (PEG). The formulations were all prepared with 1:1 AMB:cholesterol derivative mole ratios, by solvent injection, as outlined in Example 8. The particle sizes, size distributions, and microscopic appear¬ ances of the four AMB particle compositions are given in Table 13 of Example 8. LD j - values of the four compositions, and for Fungizone™ in mice was determined by evaluating lethality at increasing AMB doses. As seen from Table 14 in Example 8, all of the cholesterol derivatives reduced AMB toxicity, i.e., increased the LD JO severalfold. However, the AMB:cholesteryl sulfate composition was 2-3 times less toxic than the other AMB cholesterol formulations, as evidenced by its 2-3 times greater LD j - value. As part of the preclinical development of AMB/cholesteryl sulfate dispersion, the toxicologi- cal profile and dose-related effects of 1:1 AMB/cho¬ lesteryl sulfate dispersion, formed by solvent injection as detailed above and in Example 5, have been evaluated in three animal species. AMB, administered as amphotericin B for injection USP (Fungizone™) , was included for comparative purposes in selected AMB/cholesteryl sulfate dispersion toxicology studies. These studies provide data that support administration of AMB/cholesteryl sulfate dispersion to humans at safe and pharmacologically effective doses. Six studies, conducted in compliance with GLP regulations, are complete or in progress that provide the essential data describing the toxicology and safety limits of AMB/cholesteryl sulfate disper- sion in animals. In addition, l ~ x values were determined in five separate acute, single-dose studies in mice, and three separate 14-day repeat dose studies were conducted in rats, each at three different dose levels. These eight additional studies (in mice and rats) were conducted early in the development of AMB/cholesteryl sulfate disper¬ sion and were intended to determine dose ranges from which to design the six GLP toxicology studies. Details of the studies are given in Examples 7A-7C. Overall, the data show the AMB/cholesteryl sulfate dispersion LD j - is seven- to tenfold higher than Fungizone™, and repeated dose levels of AMB/cholesteryl sulfate dispersion which are toler¬ ated at least fivefold higher than repeated Fungizone levels, indicating that AMB/cholesteryl sulfate dispersion is significantly less toxic. Further, it was found that with AMB/cholesteryl sulfate dispersion, adverse effects can be reversed without apparent lasting sequelae, following cessa- tion of drug administration, and that the most severe effects occur at doses far in excess of those required for effective antifungal therapy. B. Clinical Studies A Phase I study to evaluate the safety of a single dose of AMB/cholesteryl sulfate dispersion administered to healthy male volunteers was conduct¬ ed, and is detailed in Example 7D. Table 12 in this example lists the incidence of the most common adverse events by dose level, from doses of 0.25 to 1.5 mg/kg body weight. In some cases, the incidence and severity appeared to be dose dependent. Other adverse events reported for the active drug which do not appear in this table were lightheadedness, and lips and tongue tingly and numb. These events were reported in the 0.25 mg/kg level only. In addition, chills and trembling sometimes were reported by those volunteers who had an elevated temperature. All laboratory tests performed were within normal limits and no clinically significant changes oc¬ curred. In patients with life-threatening systemic fungal infections, dosing with Fungizone™ is typi¬ cally started at 0.1 to 0.25 mg/kg and escalated daily up to 0.5 to 0.75 mg/kg or the maximum toler¬ ated dose. Adverse events are common at clinically relevant doses. Premedication with analgesics, such as meperidine, is typically administered to help manage acute effects such as headache, fever, and chills. For example, a retrospective survey of 115 intensively treated cancer patients receiving 91 treatment courses of Fungizone at 0.6 to 0.7 mg/kg found a high incidence of rigors/chills (90%) , fever (23%) , increased creatinine (52%) , and renal toxici- ty (51%) (Spitzer, et. al. 1989). Compared to these results, the incidence of adverse effects observed in the Phase I study with AMB/cholesteryl sulfate dispersion, at doses up to 1.5 mg/kg body weight, is consistent with the increased safety margin with AMB/cholesteryl sulfate dispersion compared to Fungizone™ which has been observed in preclinical studies. IV. Treatment Method The ability to effectively treat various disease states with the AMB/cholesteryl sulfate composition depends on a number of pharmacologic factors. The first is drug toxicity, which limits both drug dose and patient acceptance of the treat¬ ment. The studies reported above and in Example 7 indicate that the AMB/cholesteryl sulfate is admin¬ istered at substantially higher doses and/or with reduced side effects, relative to prior-art dosage forms of AMB, e.g., Fungizone™. The reduced toxici¬ ty of the drug composition is due in part to the controlled, relatively small sizes of the AMB particles (e.g., less than 100 nm) . and to the complexation with cholesteryl sulfate. The greater toxicity seen with other cholesterol derivatives complexed to AMB indicates that cholesteryl sulfate confers unique reduced-toxicity properties to AMB. A second important factor in drug efficacy is pharmacokinetics and tissue distribution. Studies aimed at these factors are given in Example 9. Briefly summarizing the results of these studies, plasma levels after intravenous injection of Fungi¬ zone™ or AMB/cholesteryl sulfate particles were higher for Fungizone in the first 12 hours post injection, but lower in the 12-36 hour after injec¬ tion. Tissue levels of drug were lower in most organs after exposure to AMB/cholesteryl sulfate dispersion, including the major site of dose-limit- ing toxicity, the kidneys. AMB levels were notably higher in the liver after AMB/cholesteryl sulfate dispersion administration compared to Fungizone. The lower levels of AMB/cholesteryl sulfate disper¬ sion observed in the kidneys after exposure to AMB/cholesteryl sulfate dispersion correlate with decreased nephrotoxicity observed for this formula¬ tion when compared to Fungizone. Thus, the AMB/cho¬ lesteryl sulfate particles appear to be taken up preferentially in the liver, which can act as a slow release depot of AMB in the bloodstream, both limited organ-specific toxicity, and extending the effective dosing interval. It is also noted, with respect to clearance of the AMB/cholesteryl sulfate, that the cholesteryl sulfate molecules in the particles are natural cho¬ lesterol components found widely in animals. The cholesterol compound has no known toxicity, and is metabolized in the body by cholesterol sulfatase. A third factor in treatment efficacy is, of course, the ability of the drug complex to inhibit or kill target pathogen in the body. A number of studies, reported below and in Example 11, demon¬ strate that AMB/cholesteryl sulfate particles have significantly enhanced drug efficacy in treating systemic fungal infection. Additional studies carried out in support of the present invention, demonstrate that the AMB/cholesteryl sulfate compo¬ sition is effective in inhibiting HIV infection in HIV-infected human peripheral blood macrophages, and is thus useful in a method for treating HIV infec¬ tion. A. Anti-Fungal Therapeutic Application The anti-fungal efficacy of AMB/cholesteryl sulfate dispersion has been compared against Fungi¬ zone in mice infected with Coccidioides immitis, Cryptococcus neoformans, Candida albicans, and Aspergillus fumigatus . Details of the treatment methods and results are given in Example 10. Briefly, in mice infected with C. immitis. Fungi- zone™ was effective in clearing coccidioidomycosis infection at 1.3 mg/kg, and was acutely toxic (50% mortality) at 2 mg/kg. AMB/cholesteryl sulfate was effective in clearing infection entirely at 5 mg/kg and no overt signs of toxicity were seen even at 10 mg/kg. The efficacy of AMB/cholesteryl sulfate disper¬ sion was compared to Fungizone™ in mice infected with Cryptococcuε neoformans , also as detailed in Example 11. Both AMB/cholesteryl sulfate dispersion and Fungizone were effective in treating murine systemic cryptococcoses with respect to prolongation of survival and reduction of organ burdens of C. neoformans. A dose of 3.2 mg/kg Fungizone was toxic, however, and resulted in death of all treated mice. AMB/cholesteryl sulfate dispersion was effective in prolonging survival and reducing organ burdens at 3.2 and 6.4 mg/kg doses, and toxicity with AMB/cholesteryl sulfate dispersion was not seen until doses were 4-6 fold higher than Fungizone (12.8 and 19.2 mg/kg). Similar results were ob¬ served in mice infected with Candida albicans and Aspergillus fumigatus, also as reported in Example 10. Thus, AMB/cholesteryl sulfate appears to be at least as effective as Fungizone™ at minimum effec¬ tive doses, and is much better tolerated at elevated doses. B. Treatment of HIV Infection Monocyte-macrophage cells which are infected with Human Immunodeficiency Virus Type I (HIV) are known to contribute to the pathogenesis of the immune deficiency associated with HIV infection (30- 32) . Monocytes originate in the bone marrow, enter and circulate in the peripheral bloodstream. Some subtypes of monocytes travel to sites such as the liver, spleen and lungs and take up residence in the blood vessels of these organs. Other monocytes migrate deep into tissues such as skin and lymph nodes. Once having taken up residence in these tissues, monocytes can differentiate into macro¬ phages. Macrophages are phagocytic mononuclear cells which actively remove and digest particulate matter such as cell debris, virus particles, bacte¬ ria and immune complexes and are critical in antigen presentation. The phagocytic action of tissue macrophages represents a key element of the host immune defense system. These cells may dysfunction by acting as a target and potential reservoir for HIV in vivo (19, 20). Monocytes-macrophage have also been implicated in the spread of HIV into the central nervous system (21) . In addition to pro¬ viding a reservoir of HIV in the body, monocytes- macrophage may also be directly involved in the destruction of T-lymphocytes by cell fusion (19) . Experiments performed in support of the present invention demonstrated that amphotericin B/choleste¬ rol derivative compositions inhibit the replication of HIV in infected macrophages, as evidenced by reduced viral production of p24 antigen in monocyte- macrophage cells infected with HIV (Example 11) . Briefly, macrophages derived from peripheral blood monocytes were infected with HIV, and treated in cell culture with AZT (obtained from the Burroughs Welcome Company) or with the above 1:1 AMB/choleste¬ ryl sulfate composition. Dilutions of the two drug compositions were added to the cells at a final drug concentration of 0.001, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 /xg/ml for AMB or 0.01, 0.1, 1, and 10 μM. AZT, immediately following washing of unbound virus inoculum from the cells. Replication of HIV in control (untreated) cell cultures was followed daily, by assay for p24 HIV antigen using a standard p24 antigen capture assay kit (17,18). In addition to using p24 as an indication of viral expression, RNA levels associated with expression of the virus can also be evaluated by slot-blot analysis (22, 23) . Efficacy of the drug action was determined by comparing the concentrations of HIV p24 in treated versus control wells, at a given multiplicity of infection. The results for AZT and AMB/cholesteryl sulfate dispersion are presented in Figure 6 and 7, respectively. The data plotted in Figure 6 indicate that AZT has the expected antiviral activity against HIV. At multiplicities of infection of 1:3125 or less, AZT at a concentration of 0.01 ,_M completely inhibits HIV replication in these macrophages. The magnitude of AZT's anti-HIV activity seen here is consistent with those reported in the literature (33) . Notice that at multiplicities of infection above 1:3125, 0.01 ,_M AZT doses not completely inhibit HIV p24 expression. AZT Λ s anti-HIV activity is clearly dependent not only on drug dose, but also on the multiplicity of infection. In the case of AMB/cholesteryl sulfate disper¬ sion (Figure 7) , HIV replication is inhibited in approximately the same concentration range as AZT. For example, at AMB/cholesteryl sulfate dispersion concentrations above 0.01 μM essentially complete inhibition of p24 expression is seen. However, in contrast to AZT, inhibition of p24 antigen expres- sion by AMB/cholesteryl sulfate dispersion is not dependant on the multiplicity of infection. At multiplicities of infection over a broad range, from 1:5 to 1:15625, O.OlμM AMB/cholesteryl sulfate dispersion is quite effective at inhibiting p24 antigen expression. This lack of dependence of AMB/cholesteryl sulfate dispersion's anti-HIV activity on the multiplicity of infection indicates an important therapeutic advantage over the nucleoside antiviral agents, exemplified here by AZT, which are less effective at high virus titers. HIV-infected patients with high viral burden, such as those experiencing episodes of elevated HIV viremia associated with the acute phase of HIV disease (that occurs within several weeks following the initial infection, often referred to as the acute retroviral syndrome) and those in the late stages of the disease, may benefit more from therapy with AMB/cho¬ lesteryl sulfate dispersion than with nucleosides anti-viral agents. The same logic would apply to health care providers who are accidently infected with HIV by needle-sticks with contaminated needles or ' surgeons who are exposed to HIV infected blood. Immediate prophylactic treatment of such patients with nucleo¬ side anti-viral agents has not proven effective in preventing the onset and progression of HIV infec¬ tion. It is believed that immediately following HIV entry into the bloodstream (whether by accidental needle-stick, sexual transmission or any other mechanism) the virus quickly infects cells express¬ ing CD4 (lymphocytes and monocyte/macrophages) and viral replication proceeds at a rapid rate. Newly formed virus particles leave infected cells, travel through the bloodstream and other fluids and infect greater and greater numbers of susceptible cells. This cycle continues unabated for several weeks since the body has not had sufficient time to mount an effective immune response (i.e., produce effec- tive concentrations of anti-HIV antibodies, a process that takes several weeks to months) . During this period the HIV titer in the bloodstream reaches very high levels and it is likely that many (perhaps the majority) of CD4 positive cells are infected. The viral burden is gradually reduced as the anti- HIV antibody levels increase and HIV disease enters its latent phase that can persist for many years. Since AMB/cholesteryl sulfate dispersion appears to be effective at inhibiting viral replica- tion at high virus titers, it would be indicated particularly for treating the acute phase of HIV- disease. Moreover, immediate administration of AMB/cholesteryl sulfate dispersion following ac¬ cidental exposure to HIV infected medical devices or body fluids would limit the fulminant progression of HIV infection characteristic of the acute phase of the disease and lessen the severity of symptoms and delay the progression of the disease. Limiting the opportunity for HIV spread by immediate AMB/choles- teryl sulfate dispersion administration following inoculation would further provide an effective prophylaxis. Cell viability data presented in Figure 7 indicate that AMB/cholesteryl sulfate dispersion is effective at inhibiting HIV replication at concen¬ trations at least two orders of magnitude lower than the cytotoxic levels of the AMB/cholesteryl sulfate dispersion composition. Studies performed to investigate the effect of AMB/cholesteryl sulfate dispersion on monocyte-macrophage cell growth demonstrated that no significant inhibition of cell growth occurred in the concentration range of 0-5 μg/ml of AMB/cholesteryl sulfate dispersion. These data suggest that there is a sizable therapeutic window (selectivity) for AMB/cholesteryl sulfate dispersion therapy. Therapeutic levels of the drug can be achieved without causing unacceptable toxici¬ ty. Pharmacokinetic studies in a 1:1 AMB/chol¬ esteryl sulfate composition indicate that when the compound is administered at a dose of 1.5 mg/kg composition, the AMB concentration remains above the in vitro minimum inactivating concentration (MIC) for at least a month. Thus it is possible to maintain effective blood levels of AMB with a dosing schedule that is reasonable for chronic therapy, as would be required to treat HIV disease. The AMB/cholesteryl sulfate dispersion composi¬ tion may be inhibiting HIV production by several mechanisms. Like other membrane-bound viruses, HIV is known to contain high amounts of cholesterol in its envelope. Depletion of cholesterol in the viral envelope is believed to reduce the infectivity of a number of such viruses (34) . The AMB/cholesteryl sulfate dispersion composition may be interacting directly with mature HIV virions in the culture medium or virus particles budding from the surface of infected cells as has been proposed for the anti- HIV activity of a lipid emulsion formulation known as AL-721 (35) . The AMB from the AMB/cholesteryl sulfate dispersion composition may enter the choles¬ terol-rich viral envelope and bind with high affini¬ ty to cholesterol. The presence of AMB-bound cho¬ lesterol in the viral envelope may disable virus particles, rendering them unable to productively fuse (enter and infect) additional cells. Alterna- tively, AMB may transfer from AMB/cholesteryl sulfate dispersion particles into sites in the surface membranes of infected cells where HIV particles are beginning to form and interfere with virus assembly. Areas of virus assembly in the membranes of infected cells are also believed to be enriched in cholesterol content. It can be appreciated from the foregoing how the ability of the AMB/cholesteryl sulfate composi- tion to inhibit HIV expression in cells can be applied to treating HIV infection in humans. The ability of the AMB/cholesteryl sulfate composition to inhibit HIV replication, either by direct inter¬ action with HIV virus particles in the bloodstream or by entering HIV infected cells, as evidenced by a substantially complete inhibition of viral antigen expression (Figure 7) in infected cells, would reduce the level of infection by reducing the production of virus particles capable of infecting new cells. Further, since the AMB/cholesteryl sulfate composition is effective to reduce expres¬ sion of HIV in monocyte-macrophage cells, treatment with the composition may be able to reduce the virus reservoirs maintained in these cells. There is evidence that HIV-infected macrophage fuse with uninfected CD4 expressing lymphoid cells in vitro which would provide an additional mechanism for CD4 lymphocyte depletion in vivo. The cell fusion process itself can lead to cell death. Depletion of the T-lymphocytes appears to be an important factor in contributing to the progression of HIV disease and the accompanying secondary consequences of opportunistic infections and neo¬ plasms (26) . HIV produced antigens presented on the macrophage cell surface have been implicated in the formation of syncytia between macrophage and CD4 T- lymphoid cells (19) . Since the AMB/cholesterol- derivative composition has the ability to inhibit and substantially eliminate expression of viral antigens in infected monocyte-macrophage cells a marked reduction in this form of cytopathology associated with AIDS would be expected. Even in those cases where infected macrophages do present local patches of HIV antigens on their surface membranes (at sites of viral assembly) , AMB deliv¬ ered in the AMB/cholesteryl sulfate dispersion composition may effectively inhibit the fusion process (and the resulting pathology associated with the formation of syncytia) by binding the excess cholesterol present at these sites. The AMB/cholesterol-derivative composition can be administered to human patients by a variety of methods and at therapeutic concentrations, as described above and in the section below. The response of the patient to treatment with the AMB/cholesterol-derivative composition can be monitored by evaluating any one or several of the following indications of HIV infection from blood samples collected during treatment of the patient (the so-called surrogate markers of HIV disease progression) : (a) HIV antigen levels, including p24, associ¬ ated with HIV-infected cells (e.g., by ELISA (17, 18); (b) HIV antigen levels in the bloodstream (17, 19) ; (c) the reverse-transcriptase activity associated with HIV-infected cells (36) ; or (d) the level of replication of the HIV-I virus as identified by RNA transcription levels of the viral genome (e.g., slot-blot hybridization (23)). (e) the level of infectious virus particles in the plasma or associated with formed elements of blood (viremia) ; (f) the CD4 cell count in peripheral blood samples. Maintenance of an antiviral response can be monitored by comparing the levels of the above indicators determined from blood samples taken from the patient before treatment with the AMB/choleste- rol-derivative composition to those during or after treatment. C. Modes of Administration The present invention provides a dehydrated AMB/cholesteryl sulfate compositions which, when rehydrated after an extended storage period, forms a suspensions of AMB particles having a selected size range less than about l micron and preferably between 40-150 nm, and more preferably between 80- 120 nm. Because the particles can be stored in an anhydrous, inert environment (or in a vacuum) , toxicity and lipid and drug breakdown problems related to oxidation and mechanical damage at a gas/liquid interface are minimized. For parenteral use, e.g., intravenous administration, the composi¬ tions were preferably formed from AMB liposomes having sizes of between about 40-400 nm, such as can be prepared by the methods above. The AMB/lipid compositions were hydrated typically to a selected AMB concentration of about 5 mg/ml and then diluted with 5% dextrose to about .63 mg/ml for infusion, and administered at a concentration of between 0.25 and 5 mg AMB/kg body weight, and more preferably about 1.0-3.0 mg/kg body weight. Where the drug is given intramuscularly, to provide slow drug release from the site of injec¬ tion, the composition is preferably rehydrated to a more concentrated form, which can be conveniently localized in an injection site. From the foregoing, it can be appreciated how various objects and features of the invention are met. The invention provides AMB formulations which have substantially reduced toxicity and greater drug efficacy than free AMB or lipid/AMB formulations described in the prior art. The enhanced therapeu¬ tic index of the drug, particularly related to reduced toxicity, allows much wider use of the drug, for example, for prophylactic treatment of immuno— compromised patients, and also provides greater therapeutic efficacy in the treatment of active systemic fungal infections. The compositions of the current invention are readily prepared, the cholesterol derivatives compo- nents in purified form are relatively inexpensive, and, being physiologically acceptable, these compo¬ sitions are naturally utilized when administered parenterally. The formulations are easily stored in dried form, and, when rehydrated, yield a particle suspensions with selected small sizes. The following examples illustrate methods of preparing, characterizing, and using the AMB/choles¬ terol derivative compositions of the invention. The examples are in no way intended to limit the scope of the invention. Materials Cholesterol 3-sulphate, sodium salt, was obtained from Sigma Chemical Co., St. Louis, MO. AMB (AMB) , USP grade was obtained from Dumex, Copenha¬ gen, Denmark. Sodium cholesteryl sulfate (SCS) was supplied by Genzy e Corp., Farmingham, MA. Choleste¬ rol hemisuccinate and cholesterol iodide were obtained from Sigma, St. Louis, MO. Sodium choles¬ terol phosphate and 2-(2-methoxyethoxy) ethyl ether of epicholesterol (cholesterol PEG) were synthesized at LTI. Edetate disodium, dihydrate (EDTA) , USP, was purchased from Spectrum Chemical Company, Gardena, CA. Trimethamine (Tris) USP, lactose monohydrate, USP, hydrochloric acid (HC1) and dimethyl sulfoxide (DMSO) , chromatographic grade, were all obtained from Mallinckrodt, Inc. St. Louis, MD. "FICOLL-HYPAQUE" was obtained from Pharmacia, Piscataway NJ. "RPMI 1640" cell culture medium was obtained from Gibco BRL, Gaithersburg MD. AZT was from the Burroughs Welcome Company. Example 1 Preparation of AMB/Cholesteryl sulfate Particles By T i-ft-Fil-a Pγ rat;Lon AMB and cholesteryl sulfate (CS) in dry powder form were weighed out and combined to give one of the four AMB:cholesteryl sulfate mole ratios listed in Table 1 below. The amount of AMB and cholesteryl sulfate added was sufficient to produce a final AMB plus cholesteryl sulfate concentration in the particle suspension of about 50 umole/ml. Dry methanol was added to the AMB/cholesteryl sulfate powder to a final AMB concentration of between 0.2-0.6 mg/ml, and the suspension was stirred until all of the powder was dissolved. Lactose was added to this solution to produce a 10% (w/v) lactose solution in the final aqueous product. The solution was dried in vacuo. yielding dried lactose particles coated with a lipophilic AMB/cho¬ lesteryl sulfate film. A suspending buffer containing 10 mM Tris-HCl, 0.1 M EDTA pH 7.4, 67 mOsm, was added to the dried mixture in an amount sufficient to produce a final AMB plus cholesteryl sulfate concentration of 50 umole/ml. This suspension was sonicated with a probe sonicator (Ultrasonic Liquid Processor, Model W-800, Heat Ultrasonics, Inc., Farmingdale, NY), until the suspension became optically clear. (This process was facilitated when the suspension was warmed to 45°C in a water bath.) Sonication was performed under nitrogen gas. The sonicatedAMB/cholesteryl sulfate particles were dialyzed to remove traces of free unincorporat¬ ed AMB, using 6000-8000 molecular weight cut-off dialysis tubing. The material was dialyzed against a buffer containing 10 mM Tris-HCl, 0.1 mM EDTA, 10% (w/v) lactose, pH 7.4, 300 mOsm. The clear suspen- sion was dried by rapid freezing in a dry ice/iso- propanol mixture and lyophilized overnight at a shelf temperature of -25oC, followed by a further two hours at 25°C (15 SRC-X Lyophilizer; Virtis, Gardiner, NY) . Lyophilized samples were reconsti- tuted by addition of an equal volume of water and gentle mixing. Table 1 below shows the AMB concen¬ trations of the four compositions, at various stages of preparation. Table 1 AMB Concentration (Ta /ral) Example 2 Particle Size Characteristics of AMB/CS Composition A. Effect of Lyophilization on Particle Size Particle sizes of the AMB/cholesteryl sulfate composi tion from Example 1 were determined by dynamic laser-ligh scattering using a Nicomp Model 200 sizer (Nicomp Instru ments Inc., Goleta, CA) . Samples prepared as described i Example 1 were typically diluted to 0.3 umole/ml for thi measurement using 10 mM Tris/HCl, 0.1 mM EDTA, 10% (w/v lactose buffer, pH 7.4. The mean particle sizes and stan dard deviations (S.D.) for the four compositions fro Example 1 are given in Table 2 below. Table 2 *Partιcle Diameter (mean 1 S.D. nm) B. Effect of Storage in Solution on Particle Size The four samples from Example 1, each containing a AMB plus cholesteryl sulfate concentration of about 5 umole/ml, were incubated at 4°C for up to eight days. A days 0, 2, 6 and 8, an aliquot of each suspension wa withdrawn, diluted to about 0.3 umole/ml, and examined fo particle size distribution, as described in Example l. Th results are shown in Table 3 below. It is seen that 1: composition is stable to particle size change, whereas th compositions containing higher molar amounts of cholester sulfate are progressively less stable on storage. Table 3 Days of Particle Diameter (mean i S.D. nm) as a Func Storage tion of AMB/CS Molar Ratio Post-Dialvsis A similar stability study was performed on the same compositions after lyophilization and reconstitution i distilled water, as in Example 1, with the results given i Table 3. C. Effect of Saline and Plasma on Particle Size The four samples from Example 1 were diluted to appro ximately 0.3 umole/ml with 0.9% (w/v) saline and thei sizes measured as in Example 2. The results are shown a the top line in Table 5 below. The four samples were also diluted 1:1 (v/v) wit human plasma and subsequently (within a few minutes o contact with the plasma) diluted with 10 mM Tris/HCl, 0. mM EDTA, 10% lactose (w/v) buffer pH 7.4, for sizing. Siz measurements, reported in Table 5 below, were made immedi¬ ately after diluting, and 20 minutes after diluting. Table 4 Particle Size (mean 1 S.D. nm) as a Treat- Function of AMB/CS Molar Ratio ment (Post-Lyophilization/Hydration) Similar size measurements were made on AMB/cholestery sulfate particles after lyophilization and rehydration wit distilled water. AMB/cholesteryl sulfate in four mola ratios, as described in Example 1, were diluted in saline or mixed with plasma, diluted in saline and suspended i buffer and the particle sizes were determined at a time and 20 minutes post-lyophilization and hydration. Th results are shown in Table 5 below. Table 5 Particle Size (mean 1 S.D. nm) as Treat¬ a Function of AMB/CS Molar Ratio ment (Post-Lyophilization/Hydration) Example 3 Structural Characteristics of AMB/CS Composition A. Encapsulation AMB/cholesteryl sulfate particles, 1:4 molar ratio were prepared as in Example 1, except that the Tris buffe medium used to suspend the dried AMB/cholesteryl sulfat mix contained 1 uCi of 14C-sucrose. The suspension wa applied to a Sephadex G50 gel exclusion column equilibrate with 10 mM Tris/HCl, o.l mM EDTA, 10% (w/v) lactose buffer pH 7.4, and the applied material was eluted with the sam buffer. The particles were eluted in the void volume which was monitored by UV absorption at 280 nm. Th samples were collected and examined for radioactivity b conventional scintillation counting. B. Osmotic Swelling AMB/cholesteryl sulfate formulations containing th four different mole ratios of AMB and cholesteryl sulfat were prepared as in Example 1, (in the usual suspensio medium containing 10% lactose) . These samples are desig nated as post-dialysis (P.D.) suspensions in Table 6 below. A portion of each sample (containing 10% lactose) was lyo philized and reconstituted in distilled water, and thes samples are designated as lyophilized and reconstitute (L.R.) in the table. The P.D. and L.R. samples were each diluted to 0.3 umole/ml with distilled water, and the size distribution of the particles immediately after dilution in the hypotonic medium, and 20 minutes after dilution was measured as in Example 1. The results are given in Table 6 below. As seen, there is no appreciable swelling, over a 20 minute incuba¬ tion period, as evidenced by an increase in mean particle size, in any of the samples examined. Combined with the results presented in Example 2 on the lack of solute encapsulation, these data indicating a lack of osmotic activity confirm that the 1:1 - 1:4 AMB/Cholesteryl sulfat compositions are not conventional liposomes. Table 6 Example 4 Biological Properties of AMB/CS Composition A. Toxicity (LD^ of the Particle Suspension Outbred male Swiss/Webster mice were obtained fro Simonsen Labs, Inc. The animals weighed approximatel 15-45 grams on the day of treatment and were between 4- weeks old. The animals were quarantined for at least thre days prior to the study, and only mice that remaine healthy during the quarantine period were used. The ani mals were given food and water ad libitum. Animal groups were treated with either a Fungizone free form of AMB obtained from Squibb suspended in steril saline or 1:4 AMB/cholesteryl sulfate composition prepare as in Example 1. In each case, the AMB concentration wa adjusted so that the selected dose of AMB (given in Tabl 7) could be administered in a final volume of 0.2 ml. Th test material was administered by a single intravenou injection via the lateral tail vein. Each dose wa administered over about 1.5 minutes. The animals were observed for signs of toxicity an death at least three times (1, 2, and 4 hour post treat ment) on the day of treatment. During the remaining obser vation period of five days, the animals were examined dail in the morning and afternoon. The test results, expresse as the ratio of number of survivors on day five:total num¬ ber of animals treated, are given in Table 7. Table 7 Number of Survivors on Day 5 Post-Injection/Total ected In a second toxicity test, mice were treated with 20 mg/kg of one of the four AMB cholesteryl sulfate formula¬ tions from Example l, with drug administration and animal monitoring being done as above. The results are presented below in Table 8. Table 8 Number of Survivors on Day 5 Post-Injection/Total Animals Injected Treatment Animals Survivors/Day 5 Total Injected Post Injection AMB/CS 1:1 molar ratio 6 6 1:2 molar ratio 5 0 1:3 molar ratio 5 1 1:4 molar ratio 5 0 B. Efficacy of the AMB/Cholesteryl sulfate Formulation Crl:CFW (SW) BR mice weighing 20-25 grams were ob¬ tained from the Charles River Breeding Laboratories and were given food and water ad libitum. C. albicans strain 30 was grown at 35°C on SDA (Sabourund Dextrose Agar) for 18 hours, and the organism was harvested and diluted with sterile nonpyrogenic saline to yield about 7 x 10?8 colony forming units in a 0.2 ml volume. Eight-ten animals per group were injected in the tail vein each with 0.2 ml of the above C. albicans mixture. Two days after the fungal injection, the animals were in¬ jected with graded doses of Fungizone or AMB cholesteryl sulfate (1:4) prepared as in Example 1. The AMB prepara¬ tions were adjusted in concentration so that each animal received a total volume of 0.1 ml, administered intrave- nously through the tail vein. The amount of AMB administered, expressed in terms o mg drug/kg body weight of the animal is given at the lef in Table 10. The animals were followed for 25 days postdru administration. The number of survivors at 25 days pe total number of test animals is shown in the Table 11 fo the two AMB preparations, and a buffer control. Table 10 Example 5 Preparing 1:1 AMB/Cholesteryl sulfate Composition Bv Solvent Injection This example describes a method -of preparation suitable for large-scale (commercial scale) production of 1:1 AMB/cholesteryl sulfate sodium salt colloidal disper¬ sion by solvent injection. A total of 300 g AMB and 158 g of CSSS (1:1 molar ratio) were dissolved in 11 Kg DMSO by heating for 0.5 hours at 50-55°C. The solution was then injected, using a gear pump, into a stainless steel jacketed processing tank containing 90 Kg of 5 mM Tris-HCl buffer, and 0.1 mM EDTA adjusted to, pH 7.4. The residual DMSO was removed by diafiltration. The dispersion was first concentrated down to about 1/4 of its volume and then diafiltered against 10 volume exchanges of the above buffer. When diafiltration had been completed, 9.5% (w/v) lactose was added in the dispersion while stirring. The volume was then adjusted to an AMB concentration of 5 mg/ml and the dispersion was sterile filtered. The resulting product was an isotonic, yellow opalescent suspension free of aggregation as examined by a phase contrast light microscope (Leitz, Dialux 20) . Electron microscopic images of negatively stained AMB/cholesteryl sulfate particles indicated the presence of disc like particles, rather than spherical liposomal structures (Figure 1) . For use as an injectable suspension, the above suspension was lyophilized. Reconstitution is in a suitable reconstitution medium, to give a final injectable suspension having the components given in Table 11 below. Table 11 Stability studies of prelyophilization material from above, and reconstituted composition were conducted. Based on the results of several ongoing stability studies, the prelyophilization liquid is stable at 8 β C for at least 12 months and at 30 β C for 4 months. The lyophilized form of AMB/cholesteryl sulfate dispersion is stable at 8°C and 30 β C for at least 12 months and 50°C for at least 6 months. Reconstituted AMB/cholesteryl sulfate dispersion is stable at 8°C or at ambient temperature, exposed to room light, for at least 7 days, and the reconstituted product is compatible with the stopper. Detailed stability data are summarized below. A. Stability of Liquid (Prelyophilized) Drug Product Stability studies of prelyophilization liquid AMB/cho¬ lesteryl sulfate dispersion were conducted with amphoteri¬ cin B at strengths of 2.5 mg/mL and 5.0 mg/mL. Individual 10-cc Type-1 clear glass vials were filled with 5 mL of the prelyophilization liquid, stoppered with siliconized grey butyl lyophilization-type stoppers, sealed with aluminum seals, and placed at various temperatures in an upright position, protected from light. At designated time points, vials were removed and assayed. For the 2.5 mg/mL prelyophilization liquid, data are available at three storage temperatures (8°C, 30°C, and 50°C) from one batch for up to 12 months. The stability profile was the same as for the 2.5 mg/mL liquid. B. storage Conditions for Prelyophilized Composition Based on stability study results the intermediate, prelyophilization liquid stored at 2°C to 8°C, protected from light, was given a 5 week expiration date. This duration is acceptable for handling and storage of the bulk prelyophilization liquid during manufacturing at the 60-L process scale. C. Stability of Lyophilized Composition Stability studies of lyophilized AMB/cholesteryl sulfate dispersion were conducted with amphotericin B strengths at 50 mg and 100 mg per vial. Individual 50-cc Type-I clear glass vials, containing the lyophilized AMB/cholesteryl sulfate dispersion, stoppered with silicon- ized grey butyl lyophilization stoppers and sealed with aluminum seals were placed at various temperatures in a upright position and protected from light. At designated time points, vials were removed and reconstituted with sterile water for injection (10 mL for 50 g/vial and 20 mL for 100 mg/vial) to yield a 5 mg/mL amphotericin B solu¬ tion. The reconstituted samples were then assayed. For the 50 mg dosage vials, data are available from two batches at three storage temperatures ( 8 β C, 30 β C, and 50°C) for up to 18 months. For the samples stored at 8°C and 30°C, all vials tested were within the product specifi¬ cations. For the 50°C samples, the amphotericin B level was the only component that did not meet the product specification beyond 6-7 months of storage. For the 100 mg dosage vials, data are available from one batch at three storage temperatures (8°C, 30°C, and 50°C) and another batch at 30°C for up to 12 months. A third batch was also stored at 30°C and data are available for 6 months. The same stability profile was obtained with amphotericin B strengths at 100 mg and 50 mg. At the two lower storage temperatures (8°C and 30°C) , all vials tested were within the product specifications. Samples stored at 50°C were stable for at least 6 months. D. Storage Conditions for Lyophilized Composition Based on these updated stability results, the expira¬ tion dating of lyophilized AMB/cholesteryl sulfate disper¬ sion stored at controlled room temperature and protected from light has been extended from 6 months to 12 months. The stability of lyophilized AMB/cholesteryl sulfate dispersion used in clinical trials will be continuously monitored to insure its integrity. E. Compatibility of Reconstituted Composition With Stopper To determine compatibility of reconstituted AMB/cho lesteryl sulfate dispersion with the stopper, stabilit studies of the reconstituted vials stored in an inverte position were conducted. Individual 50-cc Type-I clea glass vials, containing 100 mg lyophilized AMB/cholestery sulfate dispersion, were stoppered with siliconized buty stoppers and sealed with aluminum seals. The lyophilize product was reconstituted with 20 ml Sterile Water fo Injection using a sterile syringe and needle. For th light stability, the reconstituted vials were inverted an placed at 8°C or at ambient temperature exposed to roo light. Assays were performed on day 1 and day 7. For the freeze/thaw stability, the reconstituted vials were inverted and were placed at -7°C for 24 hours and were thawed at 8°C until assays were performed. All vials tested are within the product specifica¬ tions, and no trend is apparent. These results indicate that reconstituted AMB/cholesteryl sulfate dispersion is compatible with the lyophilization stopper and is stable at 8°C or at ambient temperature, exposed to room light, for at least 7 days. F. Recommended Storage Conditions While the physical and chemical data support a pro¬ longed shelf life of reconstituted AMB/cholesteryl sulfate dispersion, the product is stored in the refrigerator and is given an expiration dating of 7 days because the product is not preserved. Example 7 Toxicity of AMB/cholesteryl sulfate Composition A. Toxicity Studies in Mice The LDrø of both AMB/cholesteryl sulfate dispersion an Fungizone was determined in male and female Swiss Webste mice by evaluating lethality at 20, 30, 40, 50, 60, and 7 mg/kg for AMB/cholesteryl sulfate dispersion; and 2, 3 , 4, 5, and 7 mg/kg for Fungizone. In males, the intravenou LD J0 for AMB/cholesteryl sulfate dispersion is 36 mg/kg an for Fungizone, 2.6 mg/kg. In females, the intravenous LD 50 for AMB/cholesteryl sulfate dispersion is 38 mg/kg and for Fungizone, 2.0 mg/kg. Doses higher than 5 mg/kg Fungizone caused 100% mortality in both male and female mice. I contrast, mortality did not exceed 90% at doses as high as 70 mg/kg AMB/cholesteryl sulfate dispersion. B. Toxicity Studies in Rats The rat was used as a test species because of the existing information on amphotericin B effects in this species and its suitability for use in toxicology and pharmacokinetic studies. Compared with humans, rats appear to tolerate similar dose levels of amphotericin B (Parekh et al, 1975) . Three toxicity study studies were conducted in rats: 14, 28, and 91 days of consecutive daily dosing. Two 14-day repeat dose-ranging studies and one 14-day pharmacokinetics and tissue distribution study were per¬ formed in Sprague-Dawley rats. These showed that daily intravenous administration of up to 6.0 mg/kg AMB/choleste¬ ryl sulfate dispersion for two weeks was tolerated by rats with no observed morbidity or loss of body weight, whereas all animals that received more than 1 mg/kg Fungizone died or became moribund during these studies. In another study, rats were exposed to AMB/cholesteryl sulfate dispersion at doses of 1 and 5 mg/kg/day, and Fungizone at a dose of 1 mg/kg/day for 14 days in a compa- rison study of pharmacokinetics and tissue distribution. Clinical chemistry, hematology, and urinalysis parameters were measured during the two-week exposure and then for an additional two weeks. Changes in urea nitrogen levels and urine osmolality during the study indicated that similar renal effects occurred with 5 mg/kg AMB/cholesteryl sulfate dispersion and 1 mg/kg Fungizone; at 1 mg/kg AMB/choleste¬ ryl sulfate dispersion, urea nitrogen levels were only slightly elevated from controls. These effects correlated with tissue amphotericin B levels in all three groups and were reversed readily in all groups after cessation of dosing. Although this study showed that liver levels of amphotericin B were higher with AMB/cholesteryl sulfate dispersion than Fungizone, no indications of hepatotoxicity were observed even at a dose of 5 mg/kg AMB/cholesteryl sulfate dispersion. These studies show that rats were able to tolerate AMB/cholesteryl sulfate dispersion at levels at least sixfold higher than Fungizone after two weeks of repeated dosing. Effects of AMB/cholesteryl sulfate dispersion on the kidneys were reversible and no toxicities unique to AMB/cholesteryl sulfate dispersion were observed. A GLP study of the toxicity of 28 days of consecutive repeat dosing of AMB/cholesteryl sulfate dispersion was conducted in Sprague-Dawley rats. Both sexes were given doses of AMB/cholesteryl sulfate dispersion at 1.0, 2.5, and 5.0 mg/kg/day. As a comparison another group received 1.0 mg/kg of Fungizone. Some animals were necropsied after 28 daily doses; others were observed for an additional 14- day recovery period and then necropsied. Drug-related effects were assessed by recording body weight, food consumption, clinical observations, ophthalmoscopy, clinical pathology (hematology, clinical chemistry, and urinalysis) , gross pathology, and microscopic pathology. Dose-related elevations of urea nitrogen were observe in animals exposed to both AMB/cholesteryl sulfate disper sion and Fungizone. These changes reversed during the 14 day recovery period. Hyperplasia of the renal and urinar bladder epithelium were observed in animals exposed t AMB/cholesteryl sulfate dispersion as well as those expose to Fungizone. These hyperplasias did not reverse withi the 14 days for either formulation. No toxicities uniqu to AMB/cholesteryl sulfate dispersion were observed in thi study. The frequency and severity of drug-related effect observed after 5.0 mg/kg AMB/cholesteryl sulfate dispersio were less than or equal to those observed after 1.0 mg/k of Fungizone, indicating a fivefold margin of safety fo AMB/cholesteryl sulfate dispersion over Fungizone. Another GLP toxicity study in rats is nearing comple tion. In this study rats received 0, 2.5, 5.0, or 7. mg/kg for 91 consecutive daily doses of AMB/cholestery sulfate dispersion by intravenous bolus injection. Som animals were necropsied at the end of 91 days; the remain der will be necropsied at the completion of a 45-da recovery period. Plasma samples are being collected fo drug content analysis after 45 and 90 days of dosing and a the completion of the recovery period. C. Toxicity Studies in Dogs Four studies were conducted in beagle dogs. The do was chosen as the test species, not only because of th large reference database available, but because the dog i known to be very sensitive to toxicities induced b amphotericin B, particularly gastrointestinal effects. The single dose toxicity of AMB/cholesteryl sulfat dispersion in dogs was determined after intravenou administration as either bolus injection or slow infusio (2-3 hours). Bolus injection was at doses 5, 10, 15, an 25 mg/kg and infusion at 15 mg/kg. Assessment of th health of each animal included measurement of body weight clinical observations, clinical pathology studies (hematol ogy, clinical chemistry, and urinalysis) , gross pathology and microscopic examination of tissues in the event o death. Some effects were seen at all doses, ranging fro minor body weight loss at lower doses to severe distres which required euthanasia within seven hours of dosing wit animals receiving 25 mg/kg, and within six days with ani mals receiving 15 mg/kg by bolus injection. Slowing th rate at which the 15 mg/kg dose was administered b changing from bolus to infusion significantly reduce gastrointestinal effects and increased the survival of th animals. Clinical signs of toxicity occurred at doses of 10 mg/kg AMB/cholesteryl sulfate dispersion and higher but were absent at 5 mg/kg AMB/cholesteryl sulfate dispersion. These clinical signs were consistent with gastrointestinal irritation. Results of clinical laboratory tests, such as the concentrations of hepatic enzymes in the serum, indicated toxic effects on the liver, and abnormal blood urea nitrogen and creatinine concentrations indicated toxic effects on the kidneys. Changes in these serum chemistry parameters occurred at all AMB/cholesteryl sulfate dispersion doses, but the effects ranged from mild in the lower dose groups to severe only in the two highest bolus dose groups. Values for serum chemistry parameters increased transiently; however, there was no other indication of liver or kidney dysfunc- tion, and in all other regards, the animals were free from any adverse effects at the bolus dose of 5 mg/kg AMB/cho¬ lesteryl sulfate dispersion. Most importantly, recovery was complete from both renal and hepatic effects 14 days after dosing in all surviving animals. The post-mortem pathology in those animals euthanized earlier in the study revealed lesion consistent with hemorrhage, principally in the gastrointes tinal organs and the lungs. There was an apparent se difference in the susceptibility of these dogs to some o the adverse effects of AMB/cholesteryl sulfate dispersio when administered at high doses. The females seemed to b more resistant to the effects and had a greater facility t recover from changes in hepatic and renal function. A repeat dose study was designed to evaluate the acute toxicity of AMB/cholesteryl sulfate dispersion when administered intravenously by bolus injection daily for 14 consecutive days. This study was conducted in male and female beagle dogs at doses of 0.6, 1.2, 2.5, 5, and 10 mg/kg AMB/cholesteryl sulfate dispersion and compared with Fungizone at 0.6 mg/kg. The animals were assessed by clinical observations and measurements which included body weight, hematology, clinical chemistry, and urinalysis, and gross and microscopic pathology in animals that died or were euthanized. In the animals that received 0.6 and 1.2 mg/kg doses of AMB/cholesteryl sulfate dispersion, no adverse effects were observed or measured. In contrast, animals adminis¬ tered 0.6 mg/kg Fungizone showed severe renal toxicity; at post mortem examination, these animals also showed severe gastric and intestinal hemorrhage. Dosing with AMB/cholesteryl sulfate dispersion at 2.5 mg/kg and higher resulted in mild body weight depression, increased incidence of clinical signs of toxicity, and changes in clinical chemistry parameters associated with renal and hepatic function. However, the dogs dosed with Fungizone had toxicities and histopathologic lesions which did not become evident in AMB/cholesteryl sulfate disper¬ sion-dosed animals until doses of 10 mg/kg were reached. It was therefore concluded that the highest dose level of AMB/cholesteryl sulfate dispersion appropriate for longer term daily administration in dogs should be not greate than 2.5 mg/kg, because at this dose, the first changes i blood urea nitrogen and serum creatinine concentration were measured. It was further concluded that when pro longed, consecutive daily dosing is administered, AMB/cho lesteryl sulfate dispersion has at least a twofold margi of safety relative to Fungizone. Beagle dogs were exposed to AMB/cholesteryl sulfat dispersion for 30 consecutive days by bolus intravenou injection. Doses of 0, 0.5 1.0, and 2.0 mg/kg/day wer administered. As a comparison, another group of animal received 0.4 mg/kg/day of Fungizone. Necropsies wer performed after dogs received 30 doses. This study was a interim report of a 13-week study. Drug-related effects were assessed by observing bod weight, food and water consumption, clinical observations, vital signs, ophthalmoscopy, clinical pathology (hematolo¬ gy, clinical chemistry, and urinalysis) , gross patholog and microscopic pathology. No treatment related effects were observed in dogs exposed to AMB/cholesteryl sulfate dispersion at 0.5 mg/k for 30 days. Reversible, dose-related nephrotoxicity was observed at higher levels of AMB/cholesteryl sulfate dispersion and after Fungizone (0.4 mg/kg). No significant toxicities unique to AMB/cholesteryl sulfate dispersion were observed in this study. The magnitude of drug-related effects observed after 2.0 mg/kg AMB/cholesteryl sulfate dispersion was similar to that observed after 0.4 mg/kg Fungizone, indicating a fivefold margin of safety for AMB/cholesteryl sulfate dispersion. In this GLP study, beagle dogs of both sexes were exposed to AMB/cholesteryl sulfate dispersion for 91 consecutive days by bolus injection at doses of 0, 0.5, 1.0, and 2.0 mg/kg/day, with 0.4 mg/kg/day of Fungizone as comparison. Necropsies were performed after 91 days in four animals per sex, while two others were observed durin an additional 56 day recovery period before necropsy. Drug-related effects were assessed by observations o body weight, food and water consumption, vital signs clinical observations, ophthalmoscopy, clinical patholog (hematology, clinical chemistry, and urinalysis) , gros pathology, and microscopic pathology. Plasma concentra tions of amphotericin B were measured at several tim points during the study. All dose levels of AMB/cholesteryl sulfate dispersio and Fungizone were tolerated in this study (dogs receive up to 182 mg/kg total cumulative dose of AMB/cholestery sulfate dispersion) . No significant gross pathologi effects were observed in any group during the 13 weeks o exposure or 8 week recovery, and clinical observations wer limited to occasional occurrence of ucoid feces. Significant, dose-related nephrotoxicity was observe in all groups exposed to AMB/cholesteryl sulfate dispersio or Fungizone. Dose-dependent increases in serum creatinin and urea nitrogen, and decreases in urine osmolality an specific gravity were correlated with microscopic observa tions of tubular nephrosis and nephrocalcinosis. Th severity of these changes was somewhat greater in animal exposed to 0.4 mg/kg Fungizone than in those exposed to 2. mg/kg AMB/cholesteryl sulfate dispersion, indicating safety margin of at least fivefold for AMB/cholestery sulfate dispersion over Fungizone. Reversibility of thes lesions during the recovery period appeared to be slightl slower in animals exposed to Fungizone. Severity of lesions observed after 13 weeks o exposure to AMB/cholesteryl sulfate dispersion were no substantially increased from those after 30 days o exposure, and no irreversible drug-related effects wer observed. Minimal to mild, statistically significant alteration in platelet counts, erythrocyte counts, hematocrit, hemoglobin and haptoglobin occurred, mainly in AMB/choles teryl sulfate dispersion dosed animals. These changes wer not associated with any specific lesion, and were consid ered to be of limited clinical significance. In thi study, males appeared to be more sensitive than females t both AMB/cholesteryl sulfate dispersion and Fungizone. Exposure to AMB/cholesteryl sulfate dispersion resulted in reduced incidence of local inflammation at the injection site compared to exposure to Fungizone. The liver, spleen, lymph node, and bone marro associated macrophages were examined extensively for evidence of lipid accumulation which might occur with a lipid-based colloidal formulation. Although increased numbers of pigmented macrophages were observed in the livers of all animals exposed to 2.0 mg/kg AMB/cholesteryl sulfate dispersion by week 13, this also occurred in some animals exposed to 0.4 mg/kg Fungizone. This finding reversed during the recovery period and was not judged severe enough to achieve biological significance. No significant lipid accumulation was found to occur during 13 weeks of exposure to AMB/cholesteryl sulfate dispersion, at cumulative doses up to 182 mg/kg. Analysis of plasma samples after 30, 60, and 90 days of dosing and after 28 days of recovery demonstrated that drug plasma amphotericin B levels in animals dosed with 2.0 mg/kg AMB/cholesteryl sulfate dispersion were identical to those in animals exposed to 0.4 mg/kg of Fungizone, and that plasma levels during the recovery period fell at almost the same rate with both formulations. This study further supports the finding that dose- related effects produced by AMB/cholesteryl sulfate dispersion are qualitatively similar or identical to those observed with Fungizone, but these effects only occur at doses of AMB/cholesteryl sulfate dispersion at least times greater than Fungizone. In all of the studies conducted in mice, rats, an beagle dogs, pharmacological effects and toxicities o AMB/cholesteryl sulfate dispersion are qualitativel similar to those seen with other forms of amphotericin B; that is, the effects and toxicities were those commonl seen with the drug, and no new ones were introduced wit the AMB/cholesteryl sulfate dispersion formulation. Th renal and hepatic changes are well established dose-relate effects of amphotericin B as is the hemorrhaging seen i the beagle dog. It is most significant that, with AMB/cho¬ lesteryl sulfate dispersion, adverse effects can be reversed without apparent lasting sequelae, following cessation of drug administration, and that the most severe effects occur at doses far in excess of those likely to be required for effective antifungal therapy. D. Phase I Safety Study in Human Volunteers A Phase I study to evaluate the safety of a single dose of AMB/cholesteryl sulfate dispersion administered to healthy male volunteers was conducted at the University of Utah, Drug Research Center. Plasma samples were obtained from each subject at the beginning, mid-point, and end of drug infusion and at time points up to 28 days after admi¬ nistration. These samples were analyzed for amphotericin B content by HPLC. In this study, 23 healthy adult male volunteers were enrolled in a randomized, double-blind, placebo-controlled evaluation of AMB/cholesteryl sulfate dispersion. Safety and tolerance were assessed in six volunteers at each of 4 dose levels. At each dose level, four volunteers received the active drug and two received placebo with the exception of the 0.5 mg/kg dose level for which 3 volunteers received active drug and 2 received placebo. The dose levels were assessed sequentially to allow evaluation of safety befor administration of the next higher dose in the next group o volunteers. For ethical reasons, the investigator did no include a comparison with Fungizone. A test dose of 1 mg of AMB/cholesteryl sulfate disper sion was administered 24 hours before the administration o the study dose to determine if the volunteer had an intole rance to the study drug. Vital signs were taken before in fusion and at 1, 2, 4, 6, and 12 hours after infusion. The test dose was well tolerated in all volunteers. Tolerance to the study dose was based on physical examination, vital signs, clinical laboratory tests and adverse events. The study doses tested were 0.25, 0.5, 1.0, and 1.5 mg/kg. Vi¬ tal signs were taken prior to, at midpoint, at end of infu- sion, and at 1, 2, 4, 10, 24, and 48 hours after the end of infusion. Adverse reactions were monitored throughout the time the volunteer was in the study center and at return visits for blood sample collection. No premedication was given to any of the volunteers to minimize adverse events. No unique adverse events were reported by volunteers who received AMB/cholesteryl sulfate dispersion; they were those typically seen with Fungizone. Seventy-three percent of the volunteers receiving AMB/cholesteryl sulfate dispersion (11 of 15) had one or more adverse events reported. A total of 49 adverse events were reported for the volunteers on drug, with 41 events rated by the principal investigator as mild and 9 reported as moderate. None of the adverse events were rated as severe. Fifty percent of the volunteers receiving placebo (4 of 8) had one or more adverse events, with 10 reported as mild, 1 moderate and 1 severe. Table 12 lists the incidence of the most common ad¬ verse events by dose level. In some cases, the incidence and severity appeared to be dose dependent. Other adverse events reported for the active drug which do not appear in this table were lightheadedness, and lips and tongue tingl and numb. These events were reported in the 0.25 mg/k level only. In addition, chills and trembling sometime were reported by those volunteers who had an elevate temperature. All laboratory tests performed were withi normal limits and no clinically significant change occurred. In patients with life-threatening systemic fungal infections, dosing with Fungizone is typically started a 0.1 to 0.25 mg/kg and escalated daily up to 0.5 to 0.75 mg/kg or the maximum tolerated dose. Adverse events are common at clinically relevant doses. Premedication wit analgesics, such as meperidine, is typically administere to help manage acute effects such as headache, fever, an chills. For example, a retrospective survey of 115 intensively treated cancer patients receiving 91 treatment courses of Fungizone at 0.6 to 0.7 mg/kg found a high incidence of rigors/chills (90%) , fever (23%) , increased creatinine (52%) , and renal toxicity (51%) (Spitzer, et. al. 1989) . Compared to these results, the incidence of adverse effects observed in the Phase I study with AMB/cho¬ lesteryl sulfate dispersion is consistent with the in¬ creased safety margin with AMB/cholesteryl sulfate disper¬ sion compared to Fungizone which has been observed in preclinical studies. Pharmacokinetics of AMB/cholesteryl sulfate dispersion was also determined in the human subjects. Blood samples for analysis of drug serum levels were collected before, at midpoint, and end of infusion; and at 15 and 30 minutes, and 1, 2, 4, 7, 10, 24, and 48 hours after infusion; and then at 7, 14, 21, and 28 days after infusion. A 12-hour urine collection was obtained before administration of the study drug, and two serial total 24-hour urine collections were obtained after dosing, while the volunteer was in the study center. The plasma kinetics observed after intravenou infusion of AMB/cholesteryl sulfate dispersion in thi study were similar to those previously reported fo Fungizone: rapid distribution, large volume of distributio and long elimination half-life. Peak levels of amphoteri¬ cin B in plasma, observed at the end of the infusion, had mean values of 0.805, 0.843, 2.191, and 2.534 ug/mL after doses of 0.25, 0.5, 1.0, and 1.5 mg/kg, respectively. Rapid distribution after the infusion was followed by a biexponential elimination phase with a terminal half-life of 86 to 243 hours. AMB was detected in the plasma for 28 days following infusion of 1.0 and 1.5 mg/kg AMB/cholesteryl sulfate dispersion. Total body clearance ranged from 1.5 to 2.0 L/hour (0.018-0.043 L/hrkg) and the volume of distribution ranged from 250 to 650 liters (3.0-10.0 L/kg) . Plasma concentrations of drug increased with increas¬ ing doses of AMB/cholesteryl sulfate dispersion, resulting in a linear increase in area under the curve (AUC) over the range of doses studied. The apparent increases in half- life and volume of distribution with dose may be the result of inadequate characterization of the terminal elimination phase of the lower doses because plasma levels dropped below the level of detection. Table 12 Incidence of Adverse Events by Treat ent/Single-Doβe Study in Healthy Male Volunteers AMB/CS Dispersion Treatment Group (mα/kσϊ Number of Volun- 23 teers Example 8 Comparison of Toxicity in AMB/cholesterol Formulations The solvent injection system described in Example 5 was used to prepare AMB compositions containing 1:1 AMB with cholesterol phosphate, cholesterol hemisuccinate, and cholesterol polyethyleneglycol (PEG) , as described below. These three formulations were compared for toxicity (LD j - in mice) with the AMB/cholesteryl sulfate composition prepared in Example 5. A. Preparation Methods AMB/Cholesterol Phosphate. A total of 100 mg AMB and 53 g of cholesterol phosphate were dissolved in 12 ml DMSO and 25 ml methanol. The solvent mixture was then injected into 213 ml of buffer. Upon completion of diafiltration and concentration, it yielded about 20 ml of the colloida dispersion. The final product was slightly aggregated an required sonication before filtration. The particle siz determined by a laser particle εizer was 42 nm. Electro microscopic images of the dispersion also indicated dis shaped particles but size was much smaller than that o AMB/cholesteryl sulfate colloidal dispersion shown i Figure 1. AMB/Cholesterol Hemisuccinate. A total of 250 mg o AMB and 155 mg of cholesterol hemisuccinate was dissolve in 12 ml DMSO and 6 ml methanol. The mixture was injecte into 240 ml buffer. Upon completion of diafiltration an concentration, it yielded about 50 ml AMB/cholestero hemisuccinate colloidal dispersion. The product was fre of aggregation with mean particle size of 48 nm. Smalle disc shape particles were seen by electron microscopy. AMB/Cholesterol-PEG. A total of 125 mg of AMB and 66 mg of cholesterol PEG was dissolved in 7.6 ml DMSO and 3.8 ml of methanol. The mixture was injected into 140 ml buffer. Upon completion of diafiltration and concentra¬ tion, it yielded about 25 ml AMB/cholesterol PEG colloidal dispersion. The product was heavily aggregated and was unable to be filtered through a 0.22 micron membrane. The mean size was 132 nm with much greater size distribution (34% versus 22-26% for the other cholesterol derivative formulations) . B. Particle Characteristics The three AMB formulations were examined for particle sizes, morphological appearance, and cholesterol content, as described above, with the results shown in Table 13. Table 13 Particle Size, Size Distribution and Microscopic Appearance of AMB Colloidal Dispersion formed with Various Types of Cholesterol Derivatives 1. Particle size was determined by a Nicomp Model 200 lase particle sizer. 2. Microscopic examination was performed by a Leitz, DIALU 20 phase contrast light microscope. 3. Sample for cholesterol PEG was unfiltered due to heav aggregation. In the cholesterol phosphate, and hemisuccinate for¬ mulations, no aggregation and no crystals were observed, and particle sizes were 42 and 48, respectively. The cho¬ lesterol PEG formulation was aggregated but was free of crystals. C. Toxicity The acute toxicity of three AMB/cholesterol deriva tives formulations, plus AMB/cholesteryl sulfate, was mea sured according to the same protocol and compared to th acute toxicity of Fungizone. In two separate studies the result of which are com bined in Table 14, the LD j . (and 95% confidence interval) o AMB/cholesteryl sulfate dispersion was found to be 78.0 (4 +/- 10) mg/kg and the LD50 of Fungizone was 3.5 (2.5 +/ 0.1) mg/kg. The LD50 values for complexes with cholestero phosphate, cholesterol hemisuccinate and cholesterol polyethylene glycol were 16.2 (11-22) mg/kg, 24.7 (18 - 35) mg/kg and 23.9 (14-41) mg/kg respectively. All three cho¬ lesterol derivatives reduced the acute toxicity of AMB with respect to Fungizone, but none was less toxic than AMB colloidal dispersion (AMB/cholesteryl sulfate dispersion) . Table 14 Pharmacokinetics and tissue distribution of amphoteri¬ cin B after intravenous administration of AMB/cholesteryl sulfate dispersion have been studied in the rat and dog. A. Pharmacokinetics and Tissue Distribution Studies i Rats Two phar acokinetic studies have been conducted i rats: a single dose study and a 14-day repeat dose study. In the single dose study, Sprague-Dawley rats wer given AMB/cholesteryl sulfate dispersion by intravenou bolus injection at 1.0 or 5.0 mg/kg. As a comparison Fungizone was administered at 1.0 mg/kg. Plasma level were significantly lower in animals exposed to AMB/choles teryl sulfate dispersion compared to Fungizone during th first 12 hours. The terminal elimination half-life wa longer after AMB/cholesteryl sulfate dispersion; thus, a later timepoints (over 36 hours) drug plasma levels wer higher in AMB/cholesteryl sulfate dispersion-dosed animals. Tissue levels of drug were lower in most organs afte exposure to AMB/cholesteryl sulfate dispersion, includin the major site of dose-limiting toxicity, the kidneys. AM levels were notably higher in the liver after AMB/choleste ryl sulfate dispersion administration compared to Fungi zone. Increasing the dose of AMB/cholesteryl sulfat dispersion fivefold, from 1.0 to 5.0 mg/kg, did not resul in significantly higher plasma or kidney levels tha observed after exposure to 1.0 mg/kg Fungizone. The les than proportional increase in plasma levels observe indicates dose-dependence of AMB/cholesteryl sulfat dispersion metabolism in this species. After Fungizone administration, amphotericin B wa found to be widely distributed, mainly in the liver, lungs, spleen, and kidneys. In contrast, nearly 100% of th administered dose was recovered from the liver 30 minute after AMB/cholesteryl sulfate dispersion was administered. The lower levels of AMB/cholesteryl sulfate dispersio observed in the kidneys after exposure to AMB/cholestery sulfate dispersion correlate with decreased nephrotoxicit observed for this formulation when compared to Fungizone. In a second study in rats, amphotericin B level during a 14-day repeat dose study were significantly lowe in plasma and most tissues after administration of AMB/cho¬ lesteryl sulfate dispersion compared to an equivalent dose of Fungizone (1 mg/kg) . When the dose of AMB/cholesteryl sulfate dispersion was increased to 5 mg/kg, plasma levels and most tissue levels still did not significantly exceed those produced by 1 mg/kg of Fungizone. Drug at either dose did not accumulate in plasma. Drug plasma levels reached steady state during the dosing period. With AMB/cholesteryl sulfate dispersion, drug levels in plasma and tissue showed a somewhat longer terminal elimination half-life during the two-week washout period, compared to Fungizone. Concentrations of amphotericin B were significantly lower in the kidneys with AMB/cholesteryl sulfate disper¬ sion compared to Fungizone (both at 1 mg/kg) ; the lower kidney levels from AMB/cholesteryl sulfate dispersion were accompanied by reduced nephrotoxicity. Concentrations of amphotericin B were significantly higher in the liver with AMB/cholesteryl sulfate dispersion compared to Fungizone (both at 1 mg/kg) . While amphoteri- cin B levels in the liver were higher after AMB/cholesteryl sulfate dispersion, increased hepatotoxicity was not observed. B. Plasma Phar acokinetics Studies in Dogs In a 14-day repeat-dose study in dogs, administration of AMB/cholesteryl sulfate dispersion resulted in lower plasma levels of amphotericin B than Fungizone at equiva¬ lent doses (0.6 mg/kg). Plasma levels from AMB/cholesteryl sulfate dispersion reached steady state during the 14-day dosing period, whereas drug levels continued to rise in dogs receiving Fungizone during this period. Tissue levels of amphotericin B in the kidneys and gut, key sites of amphotericin B toxicity in the dog, were significantly lower with AMB/cholesteryl sulfate dispersion than with Fungizone at equivalent dose levels. As with the rat, lower drug levels in the kidney from AMB/cholesteryl sulfate dispersion were accompanied by reduced nephrotoxic¬ ity. With repeat dosing in dogs, higher amphotericin B levels were produced in the liver from AMB/cholesteryl sulfate dispersion compared to Fungizone at equivalent doses. However, these higher levels were tolerated without increased hepatotoxicity. When AMB/cholesteryl sulfate dispersion was administered at 5 mg/kg, dogs tolerated 7-9 times more amphotericin B in the liver before exhibiting hepatotoxicity equivalent to that seen with Fungizone at 0.6 mg/kg. Thus, AMB/cholesteryl sulfate dispersion is less hepatotoxic than Fungizone. Significantly less amphotericin B was recovered in the urine and feces after AMB/cholesteryl sulfate dispersion administration than after Fungizone. However, the fact that urinary and biliary clearance rates were the same with both indicates that renal and hepatic excretion mechanisms were unaffected. Example 10 Anti-Fungal Therapeutic Application The anti-fungal efficacy of AMB/cholesteryl sulfate dispersion has been studied in mice infected with.Coccidi- oideε immitis, Cryptococcuε neoformans, Candida albicans , and Aspergilluε fumigatus. A. Coccidioideε immitis Three studies were done to determine the maximum tolerated dose and therapeutic range of AMB/cholesteryl sulfate dispersion and Fungizone against Coccidioideε immitiε in female CD-I mice. After an initial study to determine dose tolerance, animals were infected with virulent C. immitiε and treated on days 3, 5, 7, 10, 12, and 14 post-infection with buffer controls, AMB/cholesteryl sulfate dispersion (0.22, 0.66, 1.3, 2.5, 5.0, 7.5, or 10 mg/kg), or Fungizone (0.22, 0.66, 1.3, or 2.0 mg/kg). Animals were monitored for 28 days post treatment, at which time surviving animals were killed. Lungs, livers, and spleens were removed and the burden of remaining infection determined. AMB/cholesteryl sulfate dispersion was effective in treating murine systemic coccidioidomycosis. Further, the formulation was well tolerated, and the mice did not show overt signs of toxicity. AMB/cholesteryl sulfate disper¬ sion completely cleared the infection from all animals treated i.v. with 5.0, 7.5, and 10 mg/kg. The lower doses of AMB/cholesteryl sulfate dispersion (0.22, 0.66, 1.3, and 2.5 mg/kg) significantly prolonged survival but did not completely eradicate the infection. Fungizone at 2.0 mg/kg was acutely toxic and resulted in death of 50% of the treated mice. Of those surviving treatment with 2.0 mg/kg Fungizone, all were cleared of the infection. All mice treated with 1.3 mg/kg Fungizone were completely cleared of the infection and tolerated multipl dosing at this level. Lower doses of Fungizone showed n overt toxicity, and prolonged survival but did not eradi cate the infection. In this model, AMB/cholesteryl sulfate dispersion wa not as potent as Fungizone on a mg/kg basis; at th equivalent doses of 0.66 and 1.3 mg/kg, Fungizone reduce residual organ burdens of C. immitiε more than AMB/choles teryl sulfate dispersion did. The efficacy of Fungizone however, was clearly limited by its toxicity at doses abov 1.3 mg/kg while AMB/cholesteryl sulfate dispersion wa tolerated at doses as high as 10 mg/kg. B. Cryptococcus neoformans The efficacy of AMB/cholesteryl sulfate dispersion wa compared to Fungizone in female CD-I mice infected wit Cryptococcus neoformans. Mice were infected with C. neoformans and treated on days 4, 6, 8, 11, 13, and 1 post-infection with buffer controls, AMB/cholestery sulfate dispersion (0.8, 3.2, 6.4, 12.8, or 19.2 mg/kg), o Fungizone (0.2, 0.8, or 3.2 mg/kg). Mice were observed fo toxicity for 49 days post-infection, at which time, surviving mice were killed and brain, lungs, liver, spleen, and kidneys and the burden of remaining infection deter mined. Both AMB/cholesteryl sulfate dispersion and Fungizon were effective in treating murine systemic cryptococcose with respect to prolongation of survival and reduction o organ burdens of C. neoformans . At 0.8 mg/kg, Fungizon and AMB/cholesteryl sulfate dispersion appeared to have similar effect on both prolongation of survival an reduction of organ burdens. A dose of 3.2 mg/kg Fungizon was toxic, however, and resulted in death of all treate mice. AMB/cholesteryl sulfate dispersion was effective i prolonging survival and reducing organ burdens at 3.2 an 6.4 mg/kg doses when compared to controls. Toxicity wit AMB/cholesteryl sulfate dispersion was not seen until dose were 4-6 fold higher than Fungizone (12.8 and 19.2 mg/kg). There was a significant decrease in organ burdens with hig doses of AMB/cholesteryl sulfate dispersion (12.8 and 19.2 mg/kg) when compared to the maximum tolerated dose of Fungizone. C. Candida albicans, Aspergillus fumigatus The efficacy of AMB/cholesteryl sulfate dispersion was compared to Fungizone in Balb/c mice infected with Candida albicans and Aspergillus fumigatus. Control mice received 5% dextrose injection. After infection with C. albicans, mice were treated with repeated doses of 0.5 and 2.0 mg/kg AMB/cholesteryl sulfate dispersion, 0.5 mg/kg Fungizone, 5% dextrose injection (days 2, 4, 6, 8, post-infection) or 50 mg/kg fluconazole (orally, days 2 through 9) . Results indicated that AMB/cholesteryl sulfate dispersion had equivalent efficacy to Fungizone in reducing colony forming units (cfu) in the kidneys and brains of these animals. In these studies, fluconazole was less effective than AMB/choleste¬ ryl sulfate dispersion and Fungizone in reducing kidney cfu and equally effective in lowering brain cfu. In another study, mice immunosuppressed with Depo- Medrol were infected with C. albicans. The effect of single doses of 0.5 and 10.0 mg/kg AMB/cholesteryl sulfate dispersion was compared to 0.5 mg/kg Fungizone. Signifi¬ cantly lower cfu were seen in the liver and spleen in those mice treated with 10.0 mg/kg of AMB/cholesteryl sulfate dispersion than with any other treatment. Cfu in the liver and spleen were approximately equal in animals receiving the 0.5 mg/kg AMB/cholesteryl sulfate dispersion and 0.5 mg/kg Fungizone treatments. All treated mice had signifi- cantly lower cfu than the untreated controls. Mice were immunosuppressed with Depo-Medrol an infected with A. fumigatus . More of the mice treated wit 4.0 mg/kg of AMB/cholesteryl sulfate dispersion survive compared to the controls. No toxicity was seen in any o the AMB/cholesteryl sulfate dispersion-treated mice Fungizone was toxic at 1.0 mg/kg, causing 30% of the mic to die the first day after treatment began. Example 11 Inhibition of HIV Infectivity in Macrophage Cultures This example shows the results of studies of treatin HIV infected macrophage cultures with an AMB/cholestery sulfate colloidal dispersion (AMB/cholesteryl sulfat dispersion) . A. Isolation of Monocytes and Macrophage HIV infected monocytes-macrophage were prepared essen tially as described by Crowe et al. (29) . Whole huma peripheral blood was collected from healthy donors int tubes containing an anticoagulant. The whole blood sampl was centrifuged (5000 rpm for 15 minutes) and the "buff coat" cell layer isolated with a pipet. Peripheral bloo ononuclear cells were isolated by centrifugation of th buffy-coat cell-layer over "FICOLL-HYPAQUE." The isolate cells were washed four time with serum free medium (RPM 1640) to remove any contaminating platelets. The cell were then transferred to glass petri dishes containin "RPMI 1640" medium which was supplemented with 20% feta calf serum. The plates containing the cells were incubate at 37°C for approximately one hour. The plates were the washed to remove non-adhering lymphocytes. Adheren monocytes-macrophages were recovered from the plates b washing with 5μM EDTA in phosphate buffered saline (PBS) containing 5% fetal calf serum on ice for 10 minute followed by scraping with a rubber spatula. The recovere monocytes-macrophages were then harvested by centrifuga tion, resuspended in "RPMI 1640" medium with 10% HIV(-) complete human serum, and placed in "TEFLON" coated 48 wel culture plates at approximately 2 X 10 6 cells/ml. Typical ly, cell viability had an initial decrease, over .approxi mately a week, after which the cultures achieved a stabl density which could be maintained for several months. Cel culture media were changed approximately every 7 days. B. Isolation of HIV A clinical monocytotrophic isolate of HIV designated HIV^ was used in the following experiments. The isolate was obtained from a HIV positive donor and passaged in cell culture by Pan Data Systems of Rockville, Maryland (now known as Universal Biotechnology Technology, Inc.). Stock cultures of this isolate with an approximate titer of 1 X 10 s TCID jfj /ml were stored at -70°C until use. Reverse transcriptase activity as measured essentially by the method of Hoffman (16) . C. Infection of the Monocytes-Macrophage Following adherence to the bottom surface of the multiwell culture plates, the human peripheral blood monocytes isolated as described above differentiated into macrophages with phagocytic activity and formed stable nearly confluent monolayers. Eight serial 5-fold dilution of the HIV_. stock starting at 1:5 were prepared in growth medium containing 10 μg/ml polybrene. Macrophage plates were infected by the addition of 0.2 ml/well of the virus dilutions to each well (corresponding to multiplicities of infection of: 1:5, 1:25, 1:125, 1:625, 1:3125, and 1:15625. The virus was allowed to absorb for 90 minutes at 37°C after which time the cell cultures were washed twice with serum- free medium to remove unabsorbed inoculum. D. Treatment of Infected Monocytes-Macrophage wit AMB/cholesteryl sulfate dispersion and AZT. AMB/cholesteryl sulfate dispersion was prepared as described in Example 9. Dilutions of reconstituted AMB/cholesteryl sulfate dispersion were made in sterile 5% dextrose to the following concentrations: 0.001, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 μg/ml. AZT (obtained from the Burroughs Welcome Company) was diluted in complete growth medium to concentrations of 10, 1, 0.1, and 0.01 μM. Immediately following washing of unbound virus inoculum from the cells, the medium containing the dilutions of AMB/cholesteryl sulfate dispersion or AZT were added to duplicate wells of the macrophages cultures, at each multi¬ plicity of infection (a total of 16 wells for each drug concentration) , and incubated for 10-14 days with the culture fluid being changed every 3-4 days with medium containing fresh drug at the proper dilution. Replication of HIV in control (untreated) cell cultures was followed daily. Once an acceptable control titer was achieved (i.e., >10 4 TCID^/ l) , the assay plates were lysed with Triton X-100 and assayed by a standard p24 antigen capture assay kit (17,18) . Efficacy of the drug action was determined by comparing the concentrations of HIV p2 in treated versus control wells, at a given multiplicity of infection. The results for AZT and AMB/cholesteryl sulfate dispersion are presented in Figure 6 and 7, respectively. In the case of AMB/cholesteryl sulfate dispersion (Figure 7) , HIV replication is inhibited in approximately the same concentration range as AZT. Although the invention has been described and illus¬ trated with respect to specific embodiments, uses and methods of preparation, it will be appreciated that a variety of changes and modifications may be made without departing from the scope of the invention.

Claims: IT IS CLAIMED: 1. A method of inhibiting HIV infection in peripheral blood macrophage cells, as evidenced by an inhibition of HIV p24 antigen expression in the infected cells, compris¬ ing exposing the infected cells to a composition containing particles of amphotericin B:cholesteryl sulfate, molar ratio 1:0.5 to 1:4, at a concentration of at least about 0.01 μM amphotericin B. 2. The method of claim 1, wherein the molar ratio of amphotericin B to cholesteryl sulfate is between about 1:1 and 1:2. 3. The method of claim 1, wherein the sizes of particles in the composition are between about 40-400 nm. 4. The method of claim 3, wherein the molar ratio of amphotericin B to cholesteryl sulfate is between about 1:1 and 1:2. 5. The method of claim 1, for use in treating a human subject infected with HIV, wherein the amount of said composition administered contains about 0.25-2.0 g amphotericin B/kg human subject. 6. The method of claim 5, wherein said exposing is repeated at periodic intervals until there is produced a measurable improvement in at least one of the indications of HIV infection: (a) a decrease in HIV antigen levels associated with HIV-infected cells; (b) a decrease in HIV antigen levels in the bloodstream (antigene ia) ; (c) a decrease in the titer of HIV particles in the bloodstream (viremia) ; (c) a decrease in the level of reverse-transcriptase activity associated with HIV-infected cells. (d) a decrease in the rate of HIV-induced destruction of CD4 positive T helper lymphocytes; or (e) an increase in the absolute number of CD4 positive T helper lymphocytes in the peripheral circulation. 7. The method of claim 6, wherein said exposing includes (a) producing an aqueous dispersion of amphotericin B and cholesteryl sulfate particles in a molar ratio of between 1:0.5 to 1:4, with particle sizes predominantly between 40-200 nm; (b) lyophilizing the suspension in the presence of a cryoprotectant before the particle sizes in the suspension increase substantially; and (c) reconstituting the lyophilized material with an aqueous medium to obtain a suspension of particles of sizes predominantly no larger than 400 nm.

Inventors: GUO LUKE S S, MARTIN FRANCIS J, WOODLE MARTIN C, GUO, LUKE, S., S., MARTIN, FRANCIS, J., WOODLE, MARTIN, C.
Applicants: LIPOSOME TECHNOLOGY INC, LIPOSOME TECHNOLOGY, INC.
Application year: 1992
Main classification: A61K31
IPC codes: A61K9